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Abstract 
Pathological conditions exist in which regional blood supply is reduced due to a 
decrease in arterial blood vessel lumen diameter. This may be accomplished by humoral 
or neurogenic vasoconstriction, or by arterial blood vessel hypertrophy. Adequate blood 
perfusion is important, and it is desirable to improve blood supply in these conditions. 
Rats with aortocaval fistulae (ACF) are models of heart failure in which regional blood 
supply is reduced and the renin-angiotensin-aldosterone system (RAAS) is activated. 
Attenuation of the RAAS was expected to cause a larger decrease in mean arterial 
pressure (MAP) and larger increases in regional blood flows and conductances 
(haemodynamics) in ACF rats than in sham-operated (SO) rats. Furthermore, AT 1 
receptor antagonism by losartan was expected to cause larger effects on MAP and 
regional haemodynamics than AT2 receptor antagonism by PD 123319. 
The continuous influence of angiotensin II on regional haemodynamics was 
estimated by administering captopril, losartan, and PD 1233 19 to rats with and without 
ACF. Losartan caused a larger decrease in MAP and generally larger increases in 
regional haemodynamics in rats with ACF than in SO rats. In rats with ACF, losartan 
caused a larger decrease in MAP and larger increases in regional conductances than the 
decreases produced by PD 123319. In SO rats, the increase in MAP produced by PD 
123319 was larger than the decrease produced by losartan. The increases in mesenteric 
and renal conductances produced by losartan were larger than the decreases produced by 
PD 123319. However, the decrease in iliac conductance produced by PD 123319 was 
larger than that produced by losartan. 
11 
The results of this study suggest (1) that the RAAS has a greater influence in 
controlling regional haemodynamics in rats with ACF than in SO rats and (2) that the 
RAAS is altered in rats with ACF to favor vasoconstriction, possibly as a mechanism of 
maintaining a normal mean arterial pressure despite a large decrease in total peripheral 
resistance. Finally, (3) AT 1 receptor antagonism is more effective than ACE inhibition at 
increasing regional blood flow in rats with ACF. This is important, given the goal of 
increasing regional blood supply in these rats, and may be true of other pathological 
conditions in which tissue ischaemia results from systemic vasoconstriction and 
decreased systemic blood flow. 
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1. Introduction 
1.1 . The cardiovascular system and haemodynamics 
The rat vasculature is composed of the pulmonary and systemic circulations. Each 
circuit originates at the heart with a large conducting artery that continually branches 
eventually forming smaller resistance arteries, then arterioles, and finally capillaries. 
Capillaries converge into venules, which merge to form veins. Eventually, the largest 
veins deliver blood back to the heart, which serves to propel blood throughout the 
vasculature. The right atrium and ventricle serve the pulmonary circulation, while those 
of the left heart serve the systemic circulation (Tortora and Derrickson, 201 2). 
1.1. I . Cardiac output 
The volume of blood that is ejected from a ventricle with each cardiac cycle is 
referred to as stroke volume. Cardiac output refers to the volume of blood ejected from a 
ventricle in one minute. It is the product of stroke volume and heart rate (Tor1ora and 
Derrickson, 20 12). Both stroke volume and heart rate are regulated by nervous and 
humoral mechanisms to maintain an appropriate cardiac output in changing 
circumstances (Silverthorn, 2009). Stroke volume is influenced by three factors: preload, 
contractility, and afterload (Tortora and Derrickson, 201 2). 
Preload refers to the ventricular stretch that is caused by the volume of blood in 
the ventricle immediately prior to contraction. To a limit, greater ventricular stretch 
elicits stronger ventricular contractions. As such, increasing the volume of blood in a 
ventricle causes greater ventricular stretch and more fo rcible contractions. This results in 
a greater volume of blood being expelled from the ventricle (Totiora and Derrickson, 
2012). 
Preload is influenced by venous tone and heart rate. When venous tone increases, 
reserve blood is mobilized from the highly compliant venous vasculature and the pressure 
gradient driving venous flow is increased. This increases the venous return and 
ventricular preload, causing stroke volume and cardiac output to increase (Tortora and 
Derrickson, 20 12). Decreased carotid sinus pressure, hypoxia, hypercapnia and 
circulating adrenaline and noradrenaline can increase venous return (Braunwald et al. , 
1963 ; Ross et al. , 1961 a). In contrast, increased carotid sinus pressure and elevated left 
ventricular pressure reduce venous return (Ross et al., 1961 a; Ross et al. , 1961 b). 
Contractility refers to the force with which the ventricles contract. Increasing 
contractility allows more blood to be ejected from the ventricle, increasing stroke volume 
and therefore card iac output. Sympathetic nerves release noradrenaline onto the sinoatrial 
and atrioventricular nodes, as well as contractile fibers of the heart. At the nodes, 
noradrenaline causes an increase in the spontaneous depolarization of pacemaker cells, 
whereas it causes cardiomyocytes to increase contractility. Similarly, parasympathetic 
nerves release acetylcholine onto the nodes and contractile fibers of the heart. At the 
nodes, acetylcholine causes a decrease in the spontaneous depolarization of pacemaker 
cells. However, parasympathetic nerves exert little control over contractility. In addition, 
circulating adrenaline and noradrenaline, as well as thyroid hormones, increase heart rate 
and contractility (Tortora and Derrickson, 2012). 
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Afterload refers to the arterial pressure against which the heart ejects blood. If the 
afterload is elevated, the ventricle must generate greater pressure to open the semilunar 
valve and eject blood. Consequently, stroke volume is decreased. Afterload is affected by 
nervous and humoral factors that control vascular resistance, as well as structural changes 
that increase resistance to blood flow (Tortora and Derrickson, 2012). 
Increasing heart rate can result in an increased cardiac output, as blood is ejected 
from the ventricles more frequently. However, heart rate determines the quantity of time 
available for ventricular filling. If the heart rate increases, ventricular filling and 
ventricular preload decrease resulting in a smaller stroke volume. A threshold heart rate 
exists above which ventricular filling is reduced to the point that cardiac output falls even 
though the heart is pumping rapidly (Tortora and Derrickson, 20 12). 
1.1. 2. Mean arterial blood pressure 
Mean arterial blood pressure is an estimate of the outward force applied on vessel 
walls by blood. It is the product of cardiac output and systemic vascular res istance, which 
is the force that opposes blood flow through the systemic circulation. The three major 
determinants of systemic vascular resistance are blood viscosity, blood vessel length, and 
blood vessel diameter. Vascular resistance is inversely proportional to the fourth power 
of blood vessel lumen diameter. As such, control of blood vessel diameter is very 
important; it is controlled by nervous and humoral factors (Tortora and Derrickson, 
20 12). 
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eurogenic constriction of arterioles can occur in response to decreased pressure 
m the carotid or aortic blood vessels. The parasympathetic output to the heart is 
simultaneously decreased. Conversely, increased pressure acting on aortic or carotid 
baroreceptors reduces sympathetic arterial tone and increases parasympathetic output to 
the heart. Futihermore, the chemoreceptors of the carotid and aortic bodies increase 
sympatheti c output in response to hypoxia, hypercapnia, and acidosis (Totiora and 
Derrickson, 20 12; Silverthorn, 2009). 
Blood pressure is also regulated by circulating factors. The sympathetic response 
elicited by carotid and aortic baroreceptors or chemoreceptors causes adrenaline and 
noradrenaline to be released from the adrenal medulla. The circulating catecholamines 
result in vasoconstriction (Tortora and Derrickson, 20 12). Other circulating factors such 
as : atrial natriuretic peptide, angiotensin, vasopressin, endothelin, nitric oxide (NO), and 
bradykinin can result in vasoconstriction or dilation and therefore increase or decrease 
blood pressure (Tortora and Derrickson, 2012; Meens et al. , 2009; Sampaio et al. , 2007; 
Bisset and Lewis, 1962; review: Gassanov et al. , 2011 ; Nguyen Dinh Cat and Touyz, 
2011 ; Kurdi et al., 2005 ; Willenbrock et al., 1999a). 
1.1. 3. Vascular conductance 
Vascular conductance is used as an indirect measure of vascular tone. Vascular 
resistance is the inverse of vascular conductance. Conductance is the better parameter to 
use if the observed change primarily affects blood flow, as the two are directly 
proportional and therefore linearly related. Conversely, if the vascular effects are 
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centered on changing blood pressure without significant change in flow, then vascular 
resistance is the better measurement. Choosing the appropriate parameter reduces the 
error associated with calculating average vascular conductance or resistance. Generally, 
conductance is the correct choice for in vivo experimentation (Lautt, 1989). 
1.2. The renin-angiotensin-aldosterone system 
The renin-angiotensin-aldosterone system (RAAS) serves to regulate blood 
pressure, blood volume, and renal function. Juxtaglomerular cells of renal afferent 
arterioles release renin into the circulation in response to: sympathetic stimulation, 
hypotension, reduced sod ium and chloride load at the macula densa, hypovolemia, 
hypokalaemia, or reduced renal perfusion (review: De Mello and Frohlich, 20 11; Nguyen 
Dinh Cat and Touyz, 20 11 ; Salgado et al. , 2010; Siragy and Carey, 20 10; Kurdi et al. , 
2005). Renin, an aspartyl protease, catalyzes the conversion of angiotensinogen to 
angiotensin I (Ang I). Ang I is further processed into highly vasoactive angiotensin II 
(Ang II) by the angiotensin-converting enzyme (ACE); chymase also catalyzes this 
reaction (Donoghue et al. , 2000; review: Nguyen Dinh Cat and Touyz, 2011; Rabelo et 
al. , 2011 ; Salgado et al. , 20 10; Kobori et al., 2007). Generally, Ang II binds to two 
receptors, the angiotensin II receptor type 1 (AT 1) and the angiotensin II receptor type 2 
(AT 2; Figure 1; review: Zhuo et a!. , 1998). 
In adults, AT 1 receptors predominate; they are responsible fo r the classic 
angiotensin effects. Activation of AT 1 receptors causes: vasoconstriction, aldosterone 
secretion, sodium reabsorption, thirst stimulation, sympathetic potentiation, cardiac 
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Vasoconstriction Cardiac chronotropic effects Inhibition of growth 
Aldosterone secretion ~ Gap junction conductance Inhibition of inflammation 
Vasopressin secretion Cardiovascular inflammation Inhibition of fibrosis 
If'- Blood flow 
Improve cardiac function 
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If'- Na+ reabsorption Cardiovascular hypertrophy Normal endothelial function Pro-coagulation 
Influence growth 
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Nitric oxide release 
1 Prostaglandin release 1 
:::J 
Mas receptor 
ACE 
Ang 1-9 
Figure 1. Angiotensin activation cascade and receptor signaling. 
Stimuli for activation of the angiotensin cascade are shown with a green background. Enzymes are shown in orange ovals. 
Peptides are shown in purple boxes. Receptors are shown in red rectangles. The consequences of receptor activation are shown 
with blue backgrounds. Green circles indicate activation of a receptor. 
(Adapted from: De Mello and Frohlich, 2011; Nguyen Dinh Cat and Touyz, 2011; De Mello, 2010; Ocaranza et al., 2010; 
Salgado et al., 2010; Siragy and Carey, 2010; De Mello, 2009; Kobori et al., 2007; Sampaio et al. , 2007; Duprez, 2006; Kurdi 
et al. , 2005; De Mello, 2004; Donoghue et al., 2000; Zhuo et al., 1998) 
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inotropic effects, cardiac chronotropic effects, decreased cardiac gap junction 
conductance, cardiovascular inflammation, cardiovascular hypertrophy, cardiovascular 
fibrosis, hypercoagulability, alteration of glomerular filtration rate, and vasopressin 
secretion (review: Nguyen Dinh Cat and Touyz, 2011; Salgado eta!., 2010; Siragy and 
Carey, 201 0; De Mello, 2009; Kobori et a!., 2007; Kurdi et a!., 2005). Aldosterone 
increases sodium and water reabsorption in the collecting ducts, while vasopressin causes 
water reabsorption from the collecting ducts and vasoconstriction (review: Gassanov et 
a!., 2011; Salgado eta!., 201 0; Chen and Schrier, 2006; Kurdi eta!., 2005). 
Expression of AT2 receptors is greater during fetal development (notably: brain, 
kidneys, skin, aorta, and skeletal muscle) than during adulthood (Aguilera et a!., 1994; 
review: Saavedra, 1992). However, expression of AT 2 receptors in adults tends to 
increase during: hypertension, myocardial infarction, heart failure , renal failure , cerebral 
ischemia, and diabetes, likely because AT2 receptors typically mediate effects that oppose 
those of AT1 receptors (review: Nguyen Dinh Cat and Touyz, 2011; Salgado eta!. , 2010; 
Duprez, 2006). Activation of AT2 receptors can inhibit growth, inflammation, and 
fibrosis , as well as promote normal endothelial cellular function, natriuresis, and 
vasodilation (review: Nguyen Dinh Cat and Touyz, 2011; Salgado eta!. , 2010; Siragy 
and Carey, 2010; Duprez, 2006). 
1. 2.1. AT1 receptor signaling in the cardiovascular system 
Activation of AT 1 receptors can initiate multiple intracellular signaling cascades 
resulting in cardiac and vascular: contraction, inflammation, remodeling, and hypertrophy 
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(Figure 2; view: Higuchi et a!. , 2007; Mehta and Griendling, 2007; Touyz and Berry, 
2002). The effects of AT 1 receptor activation are potentiated by dimerization with 
bradykinin B2 receptors, and inhibited by dimerization with AT2 receptors (review: 
Mehta and Griendling, 2007). 
Activation of AT 1 receptors leads to dissociation of the G proteins Ga and G~y, 
and can initiate activation of phospholipases A2, C, and D (Figure 2). Phospholipase A2 
releases arachidonic acid from membrane phospholipids. Arachidonic acid is converted 
into prostaglandin H2 by cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), 
and then further converted into various prostanoids. In a parallel pathway, lipoxygenases 
produce leukotrienes from arachidonic acid. Leukotriene intermediates can be oxidized 
by cytoclu·ome P450, the products of which counter the effects of leukotrienes. 
Collectively, AT1 receptor activation of phospholipase A2 can cause: relaxation, 
contraction, inflammation, and growth (review: Mehta and Griendling, 2007; Touyz and 
Berry, 2002). 
Phospholipase C activates two parallel pathways by cleaving membrane-derived 
phosphatidylinositol 4,5-bisphosphate into inositol 1 ,4,5-triphosphate and diacylglycerol. 
Inositol 1,4,5-triphosphate mediates calcium release from the sarcoplasmic reticulum 
resulting in: calcium-calmodulin binding, myosin light chain kinase activation, and 
smooth muscle contraction. Diacylglycerol activates protein kinase C causing an increase 
in the intracellular pH and initiation of the Ras/Raf/MECK/ERK pathway. Ultimately, 
AT 1 receptor activation of phospholipase C can cause: contraction, growth, hypertrophy, 
and inhibition of apoptosis. Furthermore, diacylglycerol serves as a source of arachidonic 
9 
Rho/ROCK 
p38MAPK 
Pathway Pathway 
AT1 Receptor Activation 
Phosphatidy lebo line 
Protein Kinase C 
10 
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Figure 2. AT 1 receptor signal transduction. 
Select enzymes are shown in orange ovals. Important signaling molecules are shown in purple boxes. Receptors are shown in 
red rectangles. Pathways are shown with a blue background. Green circles indicate activation of an enzyme, pathway, or 
receptor. PLA2: phospholipase A2; PLD: phospholipase D; PLC: phospholipase C. 
(Adapted from: Higuchi et al. , 2007; Mehta and Griendling, 2007; Touyz and Berry, 2002) 
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acid that joins the phospholipase Aractivated signaling cascade ending in relaxation, 
contraction, inflammation, and growth (review: Mehta and Griendling, 2007; Touyz and 
Berry, 2002). Phospholipase D cleaves membrane-derived phosphatidylcholine into 
phosphatidic acid and choline, the former is converted to diacylglycerol and follows the 
phospholipase C signaling cascade to alter intracellular pH and initiate the 
Ras/Raf/MECK/ERK pathway (review: Mehta and Griendling, 2007). 
Activation of AT 1 receptors and subsequent dissociation of Go. and Gpy can also 
activate the Rho/ROCK pathway. The Go. subunit can initiate activation of RhoGEFs, 
which in turn activate Rho by exchanging GTP for GDP. Rho then activates ROCK, 
which by reactive oxygen species (ROS)-dependent pathways activates JNK and 
p38MAPK. Together, the Rho/ROCK pathways result in: inflammation, hypertrophy, 
remodeling, migration, contraction, apoptosis, survival, and differentiation (review: 
Higuchi et al. , 2007; Mehta and Griendling, 2007). 
In addition, stimulation of AT 1 receptors can transactivate epidermal growth 
factor receptors (review: Higuchi et al. , 2007). Activation of AT 1 receptors results in the 
production of ROS that allow for Src activation (review: Mehta and Griendling, 2007). In 
vascular smooth muscle cells, Src and Pyk2 are needed for ADAM 17 to release an 
extracellular ligand for epidermal growth factor receptors (review: Higuchi et al. , 2007; 
Mehta and Griendling, 2007). Binding its ligand induces a conformational change in the 
receptor, promotes dimerization, and initiates autophosphorylation (review: Mehta and 
Griendling, 2007). Epidermal growth factor receptors then activate two parallel 
pathways: PI3K/PDK1 /Akt and Ras/Raf/ERK. Together, these pathways result in: 
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growth, remodeling, survival, differentiation, migration, adhesion, hypertrophy, and 
inflammation (review: Higuchi et a!., 2007; Mehta and Griendling, 2007). 
AT 1 receptor activation can activate nicotinamide adenine dinucleotide phosphate 
(NAD(P)H) oxidases that produce ROS. ROS act as signaling molecules and are 
necessary fo r signaling via p38MAPK, Akt, and epidermal growth factor receptors, as 
well as transcription factor activation. Combined, these pathways implicate ROS in: 
inflammation, survival, growth, and hypertrophy (review: Mehta and Griendl ing, 2007) . 
In endothelial cells, activation of AT1 receptors results in NAD(P)H oxidase and 
endothelial nitric ox ide synthase (eNOS) activation. Ideally, NO produced by eNOS 
would cause vasodilation. However, peroxynitrate can result from excessive production 
of ROS by NAD(P)H oxidase. ROS can cause eNOS uncoupling, in which eNOS 
inappropriately produces ROS. Excessive ROS can result in: protein damage, 
tetrahydrobiopterin deficiency, decreased intracellular nicotinamide adenine dinucleotide 
(NAD+), and decreased intracellular adenosine triphosphate. In addition to the 
detrimental effects of reduced NO availability, activation of the p38MAPK pathway can 
induce adhesion molecule production, while the ERK pathway can cause endothelin 
production and consequent vasoconstriction and growth (review: Higuchi eta!. , 2007). 
1. 2. 2. Angiotensin-converting enzyme II 
The angiotensin-converting enzyme II (ACE2) is a homologue of ACE that 
catalyzes the conversion of Ang I to angiotensin 1-9 (Ang 1-9) and Ang II to angiotensin 
1-7 (Ang 1-7; Ocaranza eta!. , 20 10; Donoghue eta!., 2000; review: Nguyen Dinh Cat 
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and Touyz, 2011 ; Rabelo eta!., 20 11 ; Salgado eta!. , 2010; Siragy and Carey, 20 10; De 
Mello, 2009; Kurdi eta!., 2005; De Mello, 2004). Through many mechanisms, ACE2 is 
believed to function in a protective role and to counteract the effects of ACE (Ocaranza et 
a!., 20 10; review: Rabelo eta!., 2011 ; Siragy and Carey, 20 10; De Mello, 2009; Kurdi et 
a!., 2005). Importantly, ACE inhibitors do not inhibit ACE2 (Ocaranza et a!. , 2010; 
Donoghue eta!. , 2000; review: Siragy and Carey, 20 10; De Mello, 2009). 
ACE2 is mostly expressed in cardiac and renal endothelial cells, as well as the 
renal epithelium. However, it is also expressed in the lungs, gastrointestinal tract, and 
testes (Donoghue et a!. , 2000; review: De Mello, 201 0; Salgado et a!. , 201 0; Siragy and 
Carey, 20 10; De Mello, 2009; Ferrario, 2006; Kurdi eta!., 2005; De Mello 2004; Oudit et 
a!., 2003). In contrast, ACE is more globally expressed in the vascular endothelium, as 
well as renal epithelial cells and cardiac cells (review: Nguyen Dinh Cat and Touyz, 
2011 ; Siragy and Carey, 20 10; De Mello, 2009; Kurdi eta!. , 2005). An isozyme of ACE 
is also expressed in the testes; it has only one catalytic site, whereas elsewhere ACE has 
two catalytic sites (Donoghue et a!., 2000). Both ACE and ACE2 cleave amino acid 
residues from the carboxyl-terminal of their substrates (review: Nguyen Dinh Cat and 
Touyz, 20 11 ; Rabelo eta!., 2011 ; De Mello, 2010; Siragy and Carey, 20 10; Salgado et 
a!. , 20 1 0; De Mello, 2009; Kurdi et a!. , 2005). Both enzymes are membrane bound, 
although they can be cleaved from the membrane to circulate throughout the vasculature 
(Ocaranza et a!. , 2010; Donoghue et a!. , 2000; review: De Mello, 2009; Oudit et a!. , 
2003). 
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Bradykinin is a peptide that can mediate vasodilation throughout the vasculature, 
at least partially via NO and arachidonic acid release following activation of bradykinin 
B2 receptors (review: Manolis et a!. , 201 0). It is degraded by ACE but not by ACE2 
(Ocaranza et a!. , 2010; Donoghue et a!. , 2000; review: Kurdi et a!., 2005). However, 
ACE2 can hydrolyze peptides other than Ang I and Ang II (Vickers et a!. , 2002; 
Donoghue et a!. , 2000). It was observed to completely hydrolyze samples of: apelin-36, 
apelin-13 , dynorphin A 1-13, neocasomorphin, ~-casomorphin, and des-Arg9-bradykinin 
in vitro . Furthermore, in vitro samples of Lys-des-Arg9 -bradykinin, ghrelin, and 
neurotensin 1-8 were partially hydrolyzed by ACE2 (Vickers et a!. , 2002). Donoghue et 
a!. (2000) also reported that ACE2 could hydrolyze kinetensin. 
Des-Arg9 -bradykinin mediates vasodilation by activation of bradykinin B 1 
receptors that are expressed during tissue damage and inflammation; the peptide is 
inactivated by ACE2 (Donoghue et al., 2000). Apelin-1 3 and apelin-36 increase 
contractility, as well as influence vascular tone and fluid balance, by activating apelin 
receptors (Vickers et al. , 2002; review: Chandrasekaran et al. , 2008). The receptors are 
expressed throughout the body, including vascular endothelial cells, vascular smooth 
muscle, and cardiomyocytes. In vivo studies have reported variable species-dependent 
effects of apelin infusion on blood pressure. Similarly, variable effects of apelin receptor 
activation on the plasma concentration of vasopressin have been reported. However, in 
vitro studies suggest that apelin receptors mediate vasodilation via NO production 
(review: Chandrasekaran et a!. , 2008). 
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1. 2. 3. Angiotensin III and IV 
Aminopeptidase A can catalyze the conversion of Ang II into angiotensin III (Ang 
III); the latter peptide can bind both AT 1 and AT 2 receptors. In vivo, it causes 
vasoconstriction, aldosterone release, and raises blood pressure. In vitro, Ang III has been 
observed to mediate cellular growth, inflammation, and extracellular matrix protein 
production (review: Nguyen Dinh Cat and Touyz, 2011). 
Aminopeptidase N can catalyze the conversion of Ang III into angiotensin IV 
(Ang IV); similarly, D-aminopeptidase can convert Ang II to Ang IV. Ang IV mediates a 
range of effects via AT 1 and angiotensin IV receptors (AT 4). It has been observed to 
increase blood flow, improve cardiac function, and cause vasodilation (review: Nguyen 
Dinh Cat and Touyz, 201 1). Ang IV may also act as a pro-coagulant and influence 
glucose metabolism and cellular growth (review: Salgado eta!. , 201 0). 
A T4 receptors are notably expressed in the endothelium (review: Duprez, 2006). 
Activation of AT 4 receptors by Ang IV or Ang II, or AT 1 receptors by Ang II, increases 
the expression of plasminogen activator inhibitor-! , a factor involved in thrombosis and 
inflammation (Mehta et a!. , 2002; review: Suzuki et a!. , 20 11 ; Salgado et a!., 20 1 0; 
Duprez, 2006). 
1. 2. 4. Angiotensin 1-9 
In addition to ACE2, cathepsin A can also produce Ang 1-9 (Ocaranza et a!., 
201 0; review: Nguyen Dinh Cat and Touyz, 20 11 ; Rabelo et al. , 2011; Salgado et a!. , 
2010; Siragy and Carey, 20 10; Kurdi eta!. , 2005). Although this peptide may not have a 
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direct effect on vascular tone, it can exert an indirect influence on haemodynamics 
(review: Salgado et al., 201 0). Simplistically, conversion of Ang I to Ang 1-9 by ACE2 
might reduce the available quantity of Ang I for conversion to Ang II by ACE. In ACE2 
knockout mice, Crackower et al. (2002) found increased concentrations of renal and 
cardiac Ang I, as well as increased concentrations of renal, cardiac, and plasma Ang II. 
The increased Ang II concentrations were not produced by increased ACE transcription . 
Unfortunately, it was not determined if Ang I expression was increased or if the lack of 
ACE2 competition for the Ang I substrate resulted in the increased concentrations. It is 
likely that both reduced competition for Ang I and reduced ACE2 degradation of Ang IT 
are responsible for the increased concentrations of Ang II. 
ACE2 competes with ACE for Ang I as a substrate, and the ACE2 product of Ang 
I hydrolysis is a competitive inhibitor of ACE (Ocaranza et al. , 201 0; Donoghue et al. , 
2000). Ang 1-9 is further hydrolyzed by ACE to form Ang 1-7 (Ocaranza et al., 201 0; 
Donoghue et al. , 2000; review: Nguyen Dinh Cat and Touyz, 20 11 ). This competitive 
inhibition would decrease the rate of other reactions catalyzed by ACE, namely Ang II 
formation and bradykinin degradation (Ocaranza et al. , 20 1 0; review: Kurdi et al. , 2005) . 
Chronic administration of Ang 1-9 following induction of myocardial infarction in male 
Sprague-Dawley rats reduced the plasma concentration of Ang II as well as plasma and 
left ventricular ACE activity (Ocaranza et al. , 20 1 0). Furthermore, beyond competitively 
inhibiting the preferential degradation of bradykinin by ACE, Ang 1-9 was observed to 
potentiate ACE-resistant bradykinin B2 receptor agonist mediated arachidonic acid and 
NO release in cultured human pulmonary artery endothelial cells. This potentiation was 
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not produced by Ang 1-9 competitive inhibition of ACE and a consequent maintenance 
of agonist concentration, as the concentration of Ang 1-9 was too low to inhibit ACE and 
the B2 receptor agonist was resistant to ACE degradation (Jackman et al., 2002). 
Ang 1-9 demonstrates anti-hypertrophic effects following myocardial infarction. 
Chronic administration of Ang 1-9 to male Sprague-Dawley rats following coronary 
artery ligation prevented left ventricular hypertrophy, as observed by decreased indices of 
left ventricular size measured in situ by echocardiography and by weight following 
excision of the heart. Conversion of Ang 1-9 into Ang 1-7 by ACE and subsequent 
binding to the Ang 1-7 receptor, Mas, did not mediate the anti-hypertrophic effect, as the 
addition of a Mas receptor antagonist did not reduce the effectiveness of Ang 1-9 
administration. However, the authors concede that Ang 1-7 can act on AT2 receptors, and 
that they did not simultaneously antagonize this receptor. Therefore, the anti-hypertrophic 
effect could be produced by Ang 1-9 conversion to Ang 1-7 by ACE, followed by Ang 1-
7 binding to AT 2 receptors. In other experiments, enalapril (ACE inhibitor) and 
candesartan (AT 1 receptor antagonist) increased the plasma Ang 1-9 concentration when 
administered chronically following myocardial infarction. This suggests that the anti-
hypertrophic effects of these drugs might be partially attributable to their ability to 
increase the concentration of circulating Ang 1-9 (Ocaranza et al. , 201 0). 
1.2.5. Angiotensin 1-7 
In addition to ACE2 production of Ang 1-7 from Ang II, neprilysin can convert 
Ang I to Ang 1-7 (Ocaranza et al. , 20 10; review: Nguyen Dinh Cat and Touyz, 20 11 ; De 
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Mello, 2011 ; Rabelo et al. , 2011 ; De Mello, 2010; Salgado et al. , 2010; Siragy and Carey, 
2010; Kurdi et al. , 2005 ; De Mello, 2004). Ang 1-7 binds Mas receptors that are 
distributed throughout the circulation, brain, heart, kidneys, liver, and testes (review: 
Nguyen Dinh Cat and Touyz, 2011 ; Rabelo et al. , 2011; De Mello, 2010; De Mello, 
2009; Kurdi et al. , 2005 ; De Mello, 2004). However, Ang 1-7 can also bind AT2 
receptors (Ocaranza et al. , 2010; review: Rabelo et al. , 2011 ). 
Together, the ACE2/Ang 1-7/Mas axis seems to oppose the ACE/Ang IIIAT 1 axis 
by reducing the concentration of available Ang II and through Mas receptor activation 
causing NO and prostaglandin release (Sampaio et al. , 2007; review: Rabelo et al. , 201 1; 
De Mello, 2009; Kurdi et al. , 2005). NO is produced in response to Mas receptor 
activation by PI3K/PKB/ Akt dependent phosphorylation of serine 11 77 and 
dephosphorylation of threonine 495 of eNOS. NO inhibits platelet aggregation, platelet 
adhesion, vascular smooth muscle proliferation, and mediates vasodilation (Sampaio et 
al. , 2007). Ang 1-7 has also been observed to prevent cardiac remodeling and 
hypertrophy (Donoghue et al. , 2000; review: De Mello, 2009; Kurdi et al. , 2005). It is 
possible for Ang 1-7 activated Mas receptors to dimerize with AT 1 receptors, thereby 
inhibiting activation ofthe AT1 receptors (review: Nguyen Dinh Cat and Touyz, 20 11). 
Ang 1-7 is believed to counter the effects of Ang II during myocardial ischaemia 
and reduce the risk of arrhythmias during reperfusion (review: De Mello, 20 1 0; De 
Mello, 2009; Kurdi et al. , 2005; De Mello, 2004). Activation of cardiac A T 1 receptors by 
Ang II decreases electrical conductance through ventricular gap junctions in hamsters. 
Similarly, intracellular administration of Ang II decreases cardiac gap junction 
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conductance (De Mello, 1996). Furthermore, Ang II and aldosterone induce inflammation 
and interstitial fibrosis that further decrease electrical conduction throughout the heart. 
Treatment with enalapril (ACE inhibitor) was observed to increase intercellular coupling. 
Ang 1-7 demonstrated antiarrhythmic properties when administered to isolated 
ventricular myocytes of cardiomyopathic hamsters; it caused hyperpolarization, increased 
conduction velocity, and increased refractoriness. However, high doses of exogenous 
Ang 1-7 were proarrhythmic (De Mello et al. , 2007). 
In heart failure, extracellular Ang II increases cellular volume by inhibiting the 
sodium pump and activating the sodium-potassium-2-chloride transporter. Ang II induced 
swelling also activates the afo rementioned chloride current. In contrast, application of 
Ang 1-7 to cells swollen by previous exposure to a hypotonic solution activates the 
sodium pump and inhibits the chloride current, thereby reducing cellular volume (review: 
De Mello, 201 0). Similarly, intracellular injection of Ang II produces the same results 
(De Mello, 2008; review: De Mello, 20 10). Therefore, the antiarrhythmic actions of Ang 
1-7 may be related to a reduction in cellular swelling (review: De Mello, 20 I 0). 
The beneficial effects of Ang 1-7 may also result from a reduction m ROS. 
Superoxide, a ROS, acts as a scavenger of excess NO; the reaction between superoxide 
and NO produces peroxynitrate. Excessive production of peroxynitrate is detrimental, it 
is known to participate in atherogenesis by oxidizing low-density lipoprotein. In addition, 
excess superoxide can decrease the availability of NO necessary to mediate vascular 
smooth muscle relaxation. As such, superox ide production fo r NO scavenging must be 
controlled (review: Rabelo et al., 2011 ) . 
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Activation of the Mas receptor by Ang 1-7 increases eNOS activity; increased 
production of NO counteracts the effect of excessive superoxide production. Mas 
deficient mice were observed to have decreased superox ide dismutase and catalase 
activity, this was accompanied by increased levels of ROS . Similarly, lipid peroxidation 
and other measures of oxidative stress were increased in mice that did not express Mas 
receptors. In these mice, NAD(P)H oxidase activity was also increased. In contrast, 
increased expression of ACE2 in the vascular smooth muscle of spontaneously 
hypertensive stroke prone rats improved endothelial function and reduced the extent of 
Ang II induced vasoconstriction. Similarly, chronic administration of Ang 1-7 to diabetic 
spontaneously hypertensive rats improved renal artery endothelial function and decreased 
renal NAD(P)H oxidase transcription and activity (Benter et al. , 2008). Ang 1-7 also 
reduced Ang II induced NAD(P)H oxidase activity in human endothelial cells (review: 
Rabelo et al. , 2011 ). However, it has also been suggested that Ang 1-7 stimulates 
oxidative stress in the kidney (Gonzales et al. , 2002). With respect to disease, chronic 
administration of Ang 1-7 seems to protect against atherosclerosis in a mouse model of 
the disease, and protect endothelial cells from Ang II induced macrophage infiltration in 
atherosclerosis (review: Rabelo et al. , 2011 ). 
1.2. 6. Local renin-angiotensin-aldosterone .systems 
Proteins and peptides of the RAAS are found extravascularly in tissues 
throughout the body, they may be extracellular or intracellular, and may be obtained from 
the circulation or synthesized locally. Of particular interest are the local RAAS of the 
21 
vasculature and heart. Angiotensin, ACE, Ang I, Ang II , as well as AT1 and AT2 
receptors are found in cardiac and vascular tissue. Furthermore, the counter-regulatory 
Ang 1-7 /Mas axis is also present in these tissues. Most of the local RAAS components 
are synthesized in the tissue, although the local synthesis of renin is debated. Also 
contributing to the local RAAS are the components that are produced in perivascular 
adipose tissue, as well as the components synthesized by immune cells in the vascular 
wall. Aside from acting on vascular tissues, the local RAAS may act directly on vascular 
neurons to influence di scharge and reuptake of noradrenaline (review: Nguyen Dinh Cat 
and Touyz, 20 11 ). 
The local RAAS can operate independently of the systemic RAAS. Local 
concentrations of angiotensin peptides can be greater than that in the plasma, this is true 
of Ang II in hypertension. In fact, the local system may be active while the systemic 
system is suppressed (review: Nguyen Dinh Cat and Touyz, 20 11 ). Increased sodium 
intake suppresses the systemic RAAS, but activates the cardiac RAAS (review: De Mel lo 
and Frohlich, 20 11 ). Simi larly, Ang II activation of A T 1 receptors of juxtaglomerular 
cells reduces renin release from these cells into the circulation, whereas activation of AT 1 
receptors in the collecting ducts increases local renin release (review: Siragy and Carey, 
2010). 
Active local RAAS can produce local effects without activation of the systemic 
RAAS. Increased sodium intake can cause structural changes in the heart before blood 
pressure increases. AT 1 receptor antagonists can prevent th is sodium induced cardiac 
remodeling (review: De Mello and Frohlich, 201 1). Similarly, hypertensive patients 
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treated with ~-blockers experienced similar decreases in blood pressure as those treated 
with ACE inhibitors or AT 1 antagonists. However, only the ACE inhibitors and AT 1 
antagonists reversed vascular remodeling. It is possible that the continuation of vascular 
remodeling in those treated with ~-blockers is produced by ongoing local RAAS activity 
independent of reduced blood pressure. Also, hypertensive patients with normal plasma 
renin activity experience a decrease in blood pressure when treated with ACE inhibitors 
or AT 1 receptor antagonists suggesting an active local and inactive systemic RAAS 
(review: Nguyen Dinh Cat and Touyz, 2011). Finally, in a transgenic mouse model with 
decreased plasma renin concentration, AT 1 receptor-dependent cardiac hypertrophy was 
observed without an increase in blood pressure (Mazzolai et al. , 1998). 
The (pro)renin receptor binds both prorenin and renin, it is expressed throughout 
the body. Activation of this receptor allows prorenin to function as renin without 
undergoing hydrolysis. As such, tissues that do not express renin can obtain prorenin 
from the circulation and then produce Ang II (review: Siragy and Carey, 2010) . In 
mesangial cells, the receptor was observed to exert a profibrotic influence independent of 
Ang II, as shown in the presence of renin and ACE inhibitors, or an AT 1 antagonist 
(Huang et al. , 2006). However, receptor expression is decreased upon excessive 
activation of (pro )renin receptors (review: Siragy and Carey, 201 0). Aside from activated 
(pro)renin receptor hydrolysis of angiotensinogen, another way in which tissues can 
avoid renin-dependent activation of the angiotensin cascade is with proangiotensin-12. 
This peptide, observed in rat aorta, can induce vasoconstriction following hydrolysis by 
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chymase and ACE to form Ang I and then Ang II (Bujak-Gizycka eta!., 2010; review: 
Nguyen Dinh Cat and Touyz, 2011 ). 
1.3. Rats with aortocaval fistulae: an experimental model of heart failure 
Heart failure describes a situation in which the heart cannot deliver sufficient 
blood to tissues throughout the vasculature. Rats with aortocaval fistulae undergo 
functional and structural cardiovascular changes similar to those of low-output congestive 
heart failure in humans (review: Abassi eta!., 2011). In fact, Melenovsky et a!. (2011) 
noted that sixty-five percent of rats with aortocaval fistulae displayed visible signs of 
heart fai lure, including lethargy and labored breathing, at twenty-two weeks after surgery. 
Some studies conducted within two weeks of introduction of aortocaval fistu lae have 
divided rats with aortocaval fi stulae into groups of sodium-excreting compensated and 
sodium-retaining decompensated rats, the latter tend to survive for less than two weeks 
(Abassi et a!., 2005; Abassi et a!. , 1998a; Abassi et a!., 1998b; Pieruzzi et a!. , 1995; 
Abassi et a!. , 1994; Hoffman et a!., 199 1; Abassi et a!. , 1990; Winaver et a!. , 1988). 
Sodium-retaining decompensated rats develop dyspnea, ascites, edema, and plural 
effusions (Abassi et a!. , 1994). Other rats with aortocaval fistulae survive longer 
(Melenovsky et a!. , 2011 ; Guo and Tabrizchi, 2008). 
1. 3.1. Haemodynamic effects ofaortocaval fistulae 
Aortocaval fistulae allow aortic blood to bypass the systemic circulation and flow 
directly into the inferior vena cava. The low resistance pathway from the arterial to the 
24 
venous vasculature significantly reduces total peripheral resistance (Ruzicka et al. , 1993; 
Huang et al. , 1992; Liu et al. , 1991 ; Flaim et al. , 1980). Increased mean circulatory filling 
pressure and decreased resistance to venous return have been observed in rats with 
aotiocaval fistulae (Guo and Tabrizchi, 2008). Consequently, right atrial pressure is 
elevated in these rats (Willenbrock et al. , 1999a; Willenbrock et al., 1999b; Huang et al. , 
1992). 
Increased venous return resul ts in an increased cardiac output (Melenovsky et al. , 
2011 ; Guo and Tabrizchi, 2008; Ruzicka et al. , 1993; Huang et al. , 1992; Liu et al., 1991; 
Flaim et al. , 1980; Flaim et al. , 1979). The majority of studies suggest that the presence 
of an aortocaval fistula has no effect on heart rate; therefore, increased cardiac output 
results from increased stroke volume (Hutchinson et al. , 20 11; Melenovsky et al. , 20 11; 
Guo and Tabrizchi , 2008; Willenbrock et al., 1999b; Ruzicka et al. , 1993; Huang et al. , 
1992; Hoffman et al. , 199 1; Liu et al. , 199 1; Flaim et al. , 1980). In time, blood volume 
increases to support the hyperdynamic circulation; there is a measurable decrease in 
hematocrit (Guo and Tabrizchi, 2008; Huang et al. , 1992). A normal mean arterial 
pressure is maintained (Chen et al. , 20 11 ; Hutchinson et al. , 20 11 ; Melenovsky et al. , 
2011 ; Guo and Tabrizchi, 2008; Willenbrock et al. , 1999a; Willen brock et al. , 1999b; 
Abassi et al. , 1994; Huang et al. , 1992; Flaim et al. , 1979). 
Left ventricular contractil ity is reduced in rats with aortocaval fistulae (Chen et 
al. , 2011 ; Hutchinson et al. , 2011 ; Melenovsky et al. , 20 11 ; Liu et al. , 199 1 ). However, 
Liu et al. (199 1) noted that the rate of change in right ventricular pressure is elevated in 
these rats. In addition, several measurements suggest diastolic dysfunction in rats with 
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aortocaval fistulae (Chen et al., 2011; Gladden et al., 2011; Hutchinson et al. , 2011; 
Melenovsky et al., 2011; Ruzicka et al., 1993 ; Liu et al. , 1991 ; Flaim et al., 1980; Flaim 
et al., 1979). 
Generally, intestinal blood flow is normal in rats with aortocaval fistu lae (Huang 
et al. , 1992). However, Flaim et al. (1979) measured reduced jejunal, but normal ileac 
and colonic blood flows at eight weeks after introduction of aortocaval fistulae . Similarly, 
decreased gastric blood flow has been observed, while splenic, hepatic and skeletal 
muscle blood flows remain normal (Huang et al., 1992; Flaim et al. , 1980; Flaim et al., 
1979). 
Renal blood flow is reduced in rats with aortocaval fistulae (Bishara et al. , 2008; 
Brodsky et al. , 1998; Abassi et al., 1997; Huang et al., 1992). Specifically, it was 
observed that cortical perfusion is reduced, while medullary blood flow is maintained at a 
normal rate (A bassi et al. , 200 1a; A bassi et al., 1998a). The altered blood flow might 
result from changes in the expression of vasoactive substances or receptors. For instance, 
transcription of ET-1 and endothelin converting enzyme mRNA is increased in the renal 
cortex of sodium-retaining decompensated rats, while the medullary transcription of both 
proteins is similar in all rats (A bassi et al. , 2001 b; A bassi et al. , 1998b ). Also, cortical and 
medullary eNOS mRNA transcription is increased in sodium-retaining decompensated 
rats, with elevated eNOS protein expression observed in the renal medulla (Abassi et al. , 
200lb; Abassi et al. , 1998a). Finally, although medullary COX-1 expression is similar in 
rats with and without aortocaval fistulae, COX-2 expression is upregulated in sodium-
retaining decompensated rats (Abassi et al., 200 l a). 
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I. 3. 2. Cardiac remodeling in rats with aortocaval fistulae 
Chen et al. (20 11) have suggested that an early cardiac inflammatory response to 
aortocaval fistulae induced haemodynamic alterations is responsible for cardiac 
remodeling. At three days after introduction of aortocaval fistulae, there is a concomitant 
increase in cardiac mast cell density, as well as the left ventricular protein expression of 
TNF-a and its receptors (McLarty et al. , 2012; Melendez et al., 2011). There is also a 
simultaneous increase in left ventricular COX-1 and -2 protein expression, as well as a 
decrease in ~ 1-integrin protein expression. Downstream products of COX-1 and -2 have 
been implicated in cardiac fibrosis , while ~ 1-integrins anchor cells to the extracell ular 
matrix thereby influencing cardiac structure and contractile coupling (McLarty et al. , 
2012). At two weeks after the introduction of aortocaval fistulae, cardiac mast cell 
density normalizes, yet matrix metalloprotease-2 and inflammatory pathways remain 
activated with elevated markers of oxidative stress and apoptosis (Lu et al. , 20 12; Chen et 
al. , 2011 ). Cardiac collagen content is reduced by the fourth week after introduction of 
aotiocaval fistulae and remains reduced (Chen et al., 2011 ; Hutchinson et al. , 201 1 ). By 
the fifth week after introduction of aortocaval fistulae, cardiac apoptosis, inflammation, 
and oxidative stress seem to normalize (Chen et al. , 201 1). However, further indications 
of ventricular remodeling have been noted at eight and fifteen weeks after introduction of 
aortocaval fistulae (Chen et al. , 20 11 ; Hutchinson et al., 20 11 ). 
Several genes have been identified as being differentially expressed in the left 
ventricle of rats with aortocaval fistulae compared to sham operated rats. Of particular 
interest, cardiac expression of inflammatory response genes were upregulated, while the 
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expressiOn of genes encoding components of fatty acid and carbohydrate metabolism 
were downregulated (McLarty et a!., 20 12; Chen et a!., 2011; Melenovsky et a!., 2011 ). 
These findings are consistent with the general state of inflammation and the observation 
of impaired mitochondrial respiration in rats with aortocaval fistulae (Gladden et a!. , 
2011 ). 
Rats with aortocaval fistulae develop left and right ventricular hypertrophy (Lu et 
a!., 20 12; McLarty et a!., 20 12; Chen et a!., 2011; Hutchinson et a!., 2011; Melendez et 
a!. , 2011 ; Melenovsky et a!. , 2011; Guo and Tabrizchi, 2008 ; Willenbrock et a!. , 1999b; 
Ruzicka eta!., 1993; Liu eta!. , 1991 ; Flaim, 1982; Flaim eta!., 1979). Liu eta! (1991) 
determined that ventricular enlargement is produced by parallel increases in myocyte 
length and width, with no change in the ratio of length to width. Alexander and Imbemba 
(1989) stated that the cardiovascular effects of aortocaval fistulae depend on: the size of 
fistula, the rate of fistula flow, the caliber of blood vessels involved, the proximity to the 
heart, and the time period that the fistula has been present. To test the effects of varying 
aortocaval fistula size, Ruzicka et a!. (1993) introduced aortocaval fistulae with eighteen 
or twenty-gauge needles. They observed that right ventricular hypertrophy was 
significantly greater in rats with larger aortocaval fistulae. Atrial enlargement has also 
been noted in these rats (Willenbrock eta!., 1999b). 
1. 3. 3. The renin-angiotensin-aldosterone system in rats with aortocaval fistulae 
The RAAS is activated in rats with aortocaval fistulae as evidenced by increased 
plasma renin activity (Abassi eta!. , 200 1b; Pieruzzi eta!. , 1995; Abassi eta!. , 1994; 
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Ruzicka et al. , 1993; Huang et al. , 1992; A bassi et al., 1990; Winaver et al. , 1988). 
Further supporting the idea that fistula size influences its cardiovascular effects, it has 
been demonstrated that larger fistulas result in greater plasma renin activity (Ruzicka et 
al., 1993). Similarly, plasma renin activity is increased in sodium-retaining 
decompensated, but not sodium-excreting compensated, rats with aortocaval fistulae 
(Abassi eta!., 2001b; Abassi eta!., 1994). Although plasma renin activity was increased, 
Pieruzzi et a!. (1995) did not measure increased plasma ACE activity . Regardless, rats 
with aortocaval fistulae have an increased plasma concentration of Ang II (Willenbrock 
et a!. , 1999b). In addition, plasma aldosterone concentration was elevated in sodium-
retaining decompensated, but not sodium-excreting compensated, rats with aortocaval 
fistulae (Pieruzzi eta!. , 1995; Winaver eta!., 1988). Furthermore, plasma concentrations 
of: epinephrine, norepinephrine and vasopressin are elevated in rats with aortocaval 
fistu lae (Bishara eta!., 2008; A bassi eta!. , 2001 b; Flaim eta!., 1979). 
1. 3. 4. The local renin-angiotensin-aldosterone system in rats with aortocaval fistulae 
The local RAAS is activated in rats with aortocaval fistulae. Increased cardiac 
transcription of renin mRNA and increased left ventricular renin activity have been 
measured (Pieruzzi et al., 1995; Ruzicka eta!. , 1993). Similarly, cardiac transcription and 
expression of ACE mRNA is upregulated in rats with aortocaval fistulae, while that of 
ACE2 is reduced (Karram et a!. , 2005; Pieruzzi et a!., 1995). Furthermore, transcription 
of AT1 receptor mRNA is increased in sodium-retaining decompensated rats. However, 
transcription of AT2 receptor mRNA is unaltered by the presence of an aortocaval fistula. 
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Similarly, the local renal RAAS may also be activated in rats with aortocaval fistulae. 
Increased renal transcription of renin mRNA has been observed, although transcription 
and protein expression of ACE is unchanged in rats with aortocaval fistulae. Similarly, no 
change in the transcription of AT1 or AT2 receptors was noted (Pieruzzi et al. , 1995). 
1. 3. 5. Natriuretic peptides in rats with aortocaval fistulae 
Compensatory mechanisms may act to reduce the effects of RAAS activation 
(Winaver et al. , 1988; review: A bassi et al. , 20 11 ). The plasma concentration of 
natriuretic peptides is elevated in rats with aortocaval fistulae (A bassi et al., 2001 b; 
Willenbrock et al. , 1999a; Willenbrock et al. , 1999b; Pieruzzi et al. , 1995; Abassi et al. , 
1994; Huang et al. , 1992; Hoffman et al. , 1991). Interestingly, the plasma concentration 
of B-type natriuretic peptide is significantly higher in sodium-retaining decompensated 
rats than in sodium-excreting compensated rats (Hoffman et al. , 1991 ). Furthermore, left 
and right ventricular and atrial transcription of atrial natriuretic peptide mRNA is 
increased in rats with aortocaval fistu lae, as is the absolute peptide content in all but the 
right ventricle. However, there is no increase in concentration when normalized to 
chamber weight (Willenbrock et al. , 1999b). Similarly, cardiac B-type natriuretic peptide 
mR A transcription is increased in rats wi th aortocaval fistu la (Hutchinson et al. , 201 1). 
1. 3. 6. Experimental findings on renal blood flow in rats with aortocaval fistulae 
Renal blood flow is regulated by many factors in rats with aortocaval fistu lae. 
Acute treatment with eprosartan, an AT 1 receptor antagonist, increased renal blood flow 
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to a greater extent and duration in rats with aortocaval fistulae than in sham-operated rats. 
A similar effect was observed with respect to cortical but not medullary blood flow, 
suggesting that Ang II acting on AT 1 receptors in the renal cortex might favor medullary 
perfusion in rats with aortocaval fistulae (Brodsky et al. , 1998). 
Furthermore, expression of ET -1 , ET -1 receptors, and eNOS in the renal medulla 
is greater than in the cortex. This might be responsible for the normal baseline medullary 
blood fl ow and augmented medullary vasodilatory response to acutely administered 
exogenous ET -1. Baseline cortical perfusion is reduced in rats with aortocaval fistulae 
and declines with ET-1 infusion (Abassi et al. , 1998a). Given the impotiance of the 
cotiex in renal function , Brodsky et al. (1998) suggested that improved cortical perfusion 
is responsible for the increased glomerular filtration observed with eprosartan treatment. 
In light of this, A bassi et al. (1998a) noted that increased expression of ET -1 and eNOS 
in the renal cortex of sodium-retaining decompensated rats might explain both the 
reduced baseline cortical perfusion and reduced constrictive response to ET -1 infusion. 
Finally, in rats with aortocaval fistulae, acute administration of an Ang II receptor 
antagonist improved the otherwise impaired renal vasodilation in response to 
endothelium-dependent or - independent 0 production. Given that the response to, and 
not production of, NO was impaired, the authors suggested that impairment of 0 
mediated renal vasodilation might also contribute to decreased renal perfusion in rats 
with aortocaval fistulae (Abassi et al. , 1997). 
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1.3. 7. Experimental findings on cardiac remodeling in rats with aortocavaljistulae 
Chronic administration of the ACE inhibitor enalapril had no effect on the 
development of cardiac hypertrophy in rats with aortocaval fistulae (Ruzicka et al. , 
1993 ). In contrast, chronic administration of the AT 1 receptor antagonist losartan 
significantly decreased the extent of left and right ventricular hypertrophy (Brodsky et al. , 
1998; Ruzicka et al. , 1993). It has been suggested that cardiac hypertrophy in the 
presence of ACE inhibition might result from ACE-independent Ang II production 
(Ruzicka et al. , 1993). However, it is also possible that ACE inhibition was inadequate at 
the tissue level. 
Chronic administration of spironolactone, an aldosterone receptor antagonist, 
increased cardiac ACE2 expressiOn and attenuated short-term cardiac hypertrophy. 
Chronic treatment with eprosartan, however, provided longer lasting anti-hypertrophic 
effects. Although spironolactone increased ACE2 expression, only eprosartan increased 
the activity of cardiac ACE2 (Karram et al., 2005). Similarly, chronic administration of 
the vasopressin V 2 receptor antagonist SR 1214638 reduced cardiac hypertrophy, 
perhaps produced by haemodynamic improvements related to decreasing blood volume 
(Bishara et al. , 2008). 
In vitro, cardiac mast cell activation by substance P was inhibited by neurokinin- I 
receptor antagonism. In rats with aortocaval fistulae, chronic neurokinin-! receptor 
antagonism prevented left ventricular collagen degradation, mast cell recruitment, and 
TNF-a expression; it is suggested that the sensory nerves that release substance P are in 
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part responsible for the inflammatory response that initiates cardiac remodeling in rats 
with aortocaval fistulae (Melendez et al. , 20 11 ). 
McLarty et al. (20 12) noted that chronic estrogen treatment in male rats, started 
before the introduction of aortocaval fi stulae, prevented or reduced the left ventricular 
expression of inflammatory genes. The expression ofTNF-a, T F-a receptor I, as well as 
COX-1 and -2 enzymes were reduced, while expression of TNF-a receptor II and P1-
integrin were increased. It was suggested that the cardioprotective actions of estrogen 
might be related to thi s favorable change in gene expression. Furthermore, Lu et al. 
(20 12) showed that chronic mast cell stabilization, prior to introduction of aortocaval 
fistulae, maintained normal left ventricular mast cell density, collagen content, and T F-
a concentration in female rats without ovaries. This suggests a link between estrogen and 
mast cell stabilization in the protection from myocardial remodeling produced by 
aortocaval fistu lae in female rats. 
1.3.8. Experimental findings on natriuretic peptides in rats with aortocavalfistulae 
In sodium-retaining decompensated rats with aortocaval fistu lae, the natriuretic 
response to acute infusion of atrial natriuretic peptide is impaired. Chronic administration 
of enalapri l for one-week significantly increased daily sod ium excretion, as well as 
improved the natriuretic response to acute treatment with atrial natriuretic peptide 
(Abassi et al. , 1990; Winaver et al. , 1988). Chronic treatment with losartan had similar 
effects (Abassi et al. , 1994). Brodsky et al. (1998) noted that AT 1 receptor antagonists 
might improve sodium excretion by: increasing renal blood flow, increasing glomerular 
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filtration rate, reducing tubular sodium reabsorption, and reducing aldosterone secretion. 
Similarly, it was noted that acute treatment with an ACE inhibitor or Ang II receptor 
antagonist restored standard responses to an acute increase in intravascular volume 
(Willenbrock et a!. , 1999b). Collectively, these results suggest that the RAAS can 
overwhelm the effects of atrial natriuretic peptide. However, the impaired atrial 
natriuretic system is important in maintaining glomerular filtration rate in rats with 
aortocaval fi stulae, as evidenced by the exaggerated effect of natriuretic peptide 
antagonism on glomerular filtration rate (Willenbrock eta!., 1999a). 
1. 3. 9. Experimental findings on bio-energetics in rats with aortocaval fistulae 
Aside from structural impairment of cardiac function, Gladden et a!. (20 11 ) 
suggest bio-energetic impairment of the heart in rats with aortocaval fistulae. They noted 
that left ventricular xanthine oxidase activity is elevated in rats with aortocaval fistu lae, 
while mitochondrial respiration and cardiac function are impaired. When modeled in 
isolated left ventricular cardiomyocytes, pretreatment with a mitochondrial antioxidant 
prevented the increase in xanthine oxidase activity, suggesting that mitochondria derived 
ROS activate xanthine oxidase. Allopurinol, a xanthine oxidase inhibitor, improved 
mitochondrial respiration and cardiac function of rats with aortocaval fi stulae. As 
xanthine oxidase can produce ROS, a positive feedback loop in which mitochondria 
derived ROS activate xanthine oxidase, whose products further impair mitochondrial 
function , could develop. As such, mitochondria might fai l to provide adequate adenosine 
triphosphate to satisfy the increased cardiac energy demand of rats with aortocaval 
34 
fistulae. Furthermore, the authors speculate that the increasing concentration of adenosine 
diphosphate might directly inhibit cardiac relaxation. Therefore, the authors suggest that 
xanthine oxidase inhibition improved mitochondrial respiration, which in turn improved 
cardiac function (Gladden et a!. , 2011 ). Interestingly, reversal of aortocaval fistulae 
results in significant improvement in haemodynamics, myocardial structure, and cardiac 
function (Hutchinson et a!. , 20 11 ; A bassi et al. , 2001 a) . 
1.4. Rationale ofthis study 
Congestive heart failure is a debilitating disease (review: A bassi et a!. , 20 II ) . 
With its high morbidity and mortality, heart failure is a burden to healthcare resources, a 
burden to financial resources, and results in lost productivity (Public Health Agency of 
Canada, 2009). More than 500 000 Canadians suffer with heart failure , and 
approximately 50 000 additional patients are diagnosed annually (Ross et a!. , 2006). In 
2005/2006 there were 54 333 hospitalizations due to heart failure in Canada (Public 
Health Agency of Canada, 2009). Given the increasing size of the elderly population, the 
frequency of hospitalization is expected to increase (Ross eta!. , 2006). 
Rats with aortocaval fistulae display several traits of human hea11 failure , 
including : neurohormonal activation, haemodynamic abnormalities, and cardiac 
remodeling (review: Abassi et a!. , 20 11 ; Hasenfuss, 1998) . However, the hyperdynamic 
circulation might be used to model other physiological conditions such as: septic shock, 
anemia, portal hypertension, severe burns, and hyperthyroidism (Palmieri et a!. , 2004; 
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Anand et al., 1995; revtew: Williams et al., 2011 ; Hollenberg et al., 2004; 
Wattanasirichaigoon et al., 2000). 
Systemic vascular flow (cardiac output - (fistula flow + bronchial flow)) is 
reduced in rats with aortocaval fistulae (Flaim et al., 1979). As such, regional perfusion is 
reduced in some vascular beds (Table 1; Bishara et al., 2008; Huang et a!. , 1992; Flaim et 
a!. , 1979). Similarly, heart failure is characterized by a decreased cardiac output, and 
results in decreased regional perfusion (review: Leier, 1992). For instance, renal blood 
flow is reduced in both human heart fai lure and this rat model (Bishara et a!. 2008; 
review: Leier, 1992). Furthermore, hepatosplanchnic perfusion is reduced in human heart 
failure, this includes blood flow to: the stomach, the small intestine, the colon, the 
pancreas, and the liver (review: Leier, 1992; Parks and Jacobson, 1985). In rats with 
aortocaval fistulae, gastric and jejunal blood flows are decreased; whereas ileac, colonic, 
and hepatic blood flows are unaffected (Huang et a!. , 1992; Flaim eta!. , 1979). 
The RAAS is activated in both human heart failure and rats with aortocaval 
fistu lae (Karram eta!. , 2005 ; Abassi eta!., 2001a; Willenbrock eta!., 1999b; Pieruzzi et 
a!. , 1995; Ruzicka et al. , 1993 ; review: Dube and Weber, 2011). Elevated plasma and 
tissue Ang II concentrations can decrease vascular conductance via direct 
vasoconstriction, sympathetic potentiation, and vascular hypertrophy (Li et a!. , 2008; 
review: Nguyen Dinh Cat and Touyz, 20 11 ; Kobori eta!. , 2007). Vascular conductance is 
rapidly modulated by direct AT1 receptor-mediated vasoconstriction and sympathetic 
potentiation (review: Touyz, 2005). 
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Table 1. Changes in regional blood flow due to aortocaval fistulae in rats. 
*significantly different from sham-operated rats 
Time Change in 
Tissue With Blood Flow Reference 
Fistula {%} 
Skeletal Muscle 
Forelimb 1 hour -55* 
1 day -22 
1 week -8 1 * 
5 weeks +60 
Hindlimb 1 hour -50* 
1 day -20 
1 week + 1060 
5 weeks -25 
Gastrocnemius 1 day -50* 2 
8 weeks -50* 3 
Biceps 1 day -14 2 
8 weeks -38 .., .) 
Triceps 1 day -47* 2 
8 weeks -56* 3 
Quadriceps 1 day -44* 2 
8 weeks -50* 3 
Latissimus dorsi 1 day -13 2 
8 weeks -58 * 3 
Psoas 1 day -62* 2 
8 weeks -6 1 * 3 
Quadriceps 1 day -44* 2 
8 weeks -50* .., .) 
Skin 
Dorsal 1 day +77 2 
Limb 1 day +32 2 
Brain 
1 hour + 19 1 
1 day -12 1 
1 week -61 * 
5 weeks +47 
Cerebellum 1 day +84* 2 
8 weeks -9 .., .) 
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Cerebrum 1 day +71* 2 
8 weeks -19 3 
Heart 
1 hour +4 
1 day +27 
1 week +48 
5 weeks -9 
Left Ventricle 1 day -53* 2 
Right Ventricle 1 day -56* 2 
Intestine 
I hour -33 
1 day -9 
1 week -63 * 
5 weeks -18 1 
Ileum 1 day +120 2 
8 weeks -20 '1 .) 
Jejunum 1 day +50 2 
8 weeks -21 * '1 .) 
Colon 1 day + 137* 2 
8 weeks +9 '1 .) 
Kidney 
1 day +29 2 
1 week -50* 4 
1 week -52* 5 
1 week -66* 6 
4 weeks -26 7 
8 weeks -19 3 
Left 1 hour -36* 
1 day -15* 1 
1 week -64* 1 
5 weeks -15 
Right 1 hour -24 
1 day -16* 
1 week -65* 1 
5 weeks -24* 1 
Cortex 1 week -30* 8 
1 week -58* 9 
Medulla 1 week -1 8 
1 week -28 9 
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Liver 
1 hour +69* 
1 day -77 
1 day +140* 2 
1 week -22 
5 weeks +53 
8 weeks ,., _ _, 3 
Spleen 
1 hour -39 
1 day +27 
1 day +4 2 
1 week -53 1 
5 weeks +5 1 
8 weeks +9 3 
Stomach 
1 hour -30 
1 day -52* 
1 day +8 2 
1 week -45* 1 
5 weeks -14 
8 weeks -45* ,., 
-' 
Testicle 
1 day +49 2 
8 weeks -31 * 3 
Left 1 hour -41 * 
1 day -23* 
1 week -62* 
5 weeks -8 
Right 1 hour -50* 
1 day -18* 
1 week -54* 2 
5 weeks +4 3 
(1: Huang et al. , 1992; 2: Flaim et al. , 1980; 3: Flaim et al. , 1979; 4: Brodsky et al. , 1998; 
5: Abassi et al. , 1997; 6: Bishara et al. , 2008; 7: Willenbrock et al. , 1999a; 8: Abassi et 
al., 200 1 a; 9: A bassi et al. , 1998a) 
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Acutely, Ang II causes vasoconstriction of the supenor mesenteric and renal 
arteries of healthy rats, but not of the hindquarters (Table 2; Takemoto, 1999). However, 
acute ACE inhibition suggests that Ang II does not continuously influence the mesenteric 
and hindquarters blood flows and vascular resistances in healthy rats or in rats with 
myocardial infarction-induced heart failure (Nelissen-Vrancken et a!., 1992). In contrast, 
ACE inhibition, AT1 receptor antagonism, and AT2 receptor antagonism suggest that the 
renal blood flow and vascular resistance of healthy rats and those wi th myocardial 
infarction or aortocaval fi stula-induced heart failure are continuously regulated by Ang II 
(Brodsky et al. , 1998; Mento et al. , 1996; Nelissen-Vrancken et al. , 1992). In humans, 
however, Ang II continuously regulates blood flow through the superior mesenteric 
artery, but not the renal artery, in healthy subjects and those with heart failure (Houghton 
et al. , 1999; Ray-Chaudhuri et a!. , 1993 ). The increase in renal blood flow and decrease 
in renal vascular resistance with AT 1 receptor antagonism was greater in rats with 
aortocaval fistu lae than in sham-operated rats, suggesting that Ang II has a greater 
influence over these parameters in rats with aortocaval fistulae than in sham-operated rats 
(Brodsky et al. , 1998). 
1. 4. 1. Hypothesis 
Given that the RAAS is activated in rats with aortocaval fistulae, acute 
attenuation of the RAAS was expected to cause larger changes in regional blood flows 
and conductances of rats with aortocaval fistulae than sham-operated rats. AT1 receptor 
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Table 2. Changes in regional blood flows and vascular resistances due to Ang II infusion, ACE inhibition, or Ang II receptor 
antagonism. 6Q: change in blood flow; 6R: change in resistance; HF: heart failure; MI: myocardial infarction; ACF: 
aortocaval fistula; NS: no significant change reported. 
*significantly different from the baseline value 
Ang II Infusion ACE Inhibition AT 1 Receptor AT 2 Receptor Blood Species Status Antagonism Antagonism Reference Vessel ~R ~Q ~R ~Q ~R ~Q ~R 
{%) (%} (%} (%) (%) (%} (%) 
Superior Rat Healthy +188* 1 
Mesenteric 0 -3 2 
Artery HF (MI) +1 +3 2 
Human Healthy +69* -37* 3 
HF +23* 0 4 
Hindquarters Rat Healthy +14 1 
-5 +3 2 
HF (MI) +2 -1 2 
Renal Rat Healthy +239* 1 
Artery +13* -12* 2 
+22* -24* 5 
+6 -18* -4 -2 6 
HF (MI) +10* -11 * 2 
+4 -18* -4 -11 * 6 
HF (ACF) +35* -33* 5 
Human HF NS NS 4 
(1: Takemoto, 1999; 2: Nelissen-Vrancken et al. , 1992; 3: Ray-Chaudhuri et al. , 1993; 4: Houghton et al. , 1999; 5: Brodsky et 
al. , 1998; 6: Mento et al. , 1996) 
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antagonism should cause blood flows and conductances to increase, while AT 2 receptor 
antagonism should cause regional blood flows and conductances to decrease. 
As systemic blood flow is decreased in rats with aortocaval fistulae, the increases 
in regional blood flows and conductances produced by AT 1 receptor antagonism were 
expected to be larger than the decreases in regional blood flows and conductances 
produced by AT 2 receptor antagonism. A similar result was expected in sham-operated 
rats, as the AT 1 receptor antagonist eprosartan had been shown to increase renal blood 
flow in rats, while renal blood flow was unchanged by the AT 2 receptor antagonist PD 
123319(Brodskyetal., 1998;Mentoetal., 1996). 
1. 4. 2. Objectives 
To compare the changes in regional (mesenteric, renal, and hindquarter) blood 
flows and conductances produced by (a) the ACE inhibitor captopril, (b) the AT, receptor 
antagonist losa1ian, and (c) the AT2 receptor antagonist PD 123319, between sham-
operated and aortocaval fistulae rats. 
To compare the changes in regional blood flows and conductances produced by 
the AT 1 receptor antagonist losartan to those produced by the AT 2 receptor antagonist PD 
123319 in (a) sham-operated rats, and in (b) rats with aortocaval fistu lae. 
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2. Materials and methods 
All procedures on animals were carried out in accordance with the guidelines of 
the Canadian Council on Animal Care, with the approval of the Institutional Animal Care 
Committee of Memorial University ofNewfoundland. 
2.1. Establishment of aortocaval fistulae 
Aortocaval fistulae were established similar to the method of Guo and Tabrizchi 
(2008). Male Sprague Dawley rats (5-6 weeks, 190-243 g) were anaesthetized with 
isoflurane (induction: 5% in 100% oxygen; maintenance: 1.5% in 100% oxygen wi th 
adjustments to maintain surgical anaesthesia) . Heparin (0.25 mL, 100 units/mL, in 
normal saline; 0.9% sodium chloride in water) was injected subcutaneously prior to 
creating a midline abdominal incision. The abdominal aorta and inferior vena cava were 
exposed and dissected free from surrounding tissues inferior to the left renal vasculature 
and superior to the aortic bifurcation. Vascular clamps were placed at these locations to 
stop blood flow through the abdominal aorta and inferior vena cava. 
In sham-operated rats, a 20G 1 needle was advanced through the left aortic wall 
into the aortic lumen, approximately midway between the left renal vasculature and the 
aortic bifurcation, and then withdrawn. To establish aortocaval fistulae, the needle was 
further advanced through the right aortic and left vena caval walls into the vena caval 
lumen. In all rats, the puncture in the left aortic wall was closed with polypropylene 
suture (6-0, Ethicon, USA). Generally, the vascular clamps were removed within fi ve 
minutes of placing them on the abdominal aorta and inferior vena cava. Fistula formation 
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was verified by: visible mixing of bright arterial blood and dark venous blood, or bright 
arterial blood flowing backwards into the iliolumbar veins upon compression of the 
inferior vena cava inferior to the left renal vasculature. 
The abdominal muscle was closed with simple running sutures of chromic gut (3 -
0, Syneture, USA), and the skin was closed with horizontal mattress sutures of braided 
silk (3-0, Surgical Specialties Corporation, USA). Bupivacaine (1 % in normal saline) was 
applied topically to the abdominal muscle and skin. Buprenorphine (0.2 mL, 0.5 mg/mL, 
in normal saline) was injected subcutaneously immediately foll owing surgery and at 
twelve-hour intervals (0 .15 mL, 0.5 mg/mL, in normal saline) for thirty-six hours. Ten 
percent of the rats with aortocaval fi stulae died within five weeks of introduction of 
aortocaval fistulae. 
2.2. Surgical preparation 
Following a recovery period (5-7 weeks), experiments were conducted with 
surgical preparation similar to other studies (McClure eta!. , 20 11; Guo and Tabrizchi, 
2008). Rats (sham: 485 ± 5 g, n=38; fistula: 475 ± 5 g, n=32) were anaesthetized with 
isoflurane (induction: 5% in 100% oxygen; maintenance: 1.5% in 100% oxygen with 
adjustments to maintain surgical anaesthesia). An incision between the ventral right upper 
thigh and pelvis provided access to the right external iliac vein and artery, which were 
catheterized with polyethylene tubing (PESO; Becton Dickinson and Company, USA) for 
intravenous injection and blood pressure measurement, respectively. Both catheters were 
filled with heparinized normal saline (25 units/mL). Isoflurane administration was 
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stopped and thiobutabarbital sodium (80 mg/mL, in 160 ~L 1 M sodium hydroxide and 
840 ~L normal saline) was periodically injected intravenously throughout surgery (sham-
operated total: 95-139 mg/kg; aortocaval fi stulae total: 81-137 mg/kg), as per lab 
protocol. An incision of the ventral neck provided access to the trachea between the 
submaxillary glands; the trachea was catheterized inferior to the isthmus of thyroid with a 
fourteen-gauge Teflon LV. catheter (Abbott Hospitals, Inc., USA). 
A midline abdominal incision from the x iphoid process to the bladder provided 
access to: the left renal artery, the abdominal aorta, the superior mesenteric artery, and 
the left common iliac artery. The arieries were dissected free from surrounding tissues 
and a transit-time perivascular flow probe (renal artery: MA1PRB; mesenteric artery: 
MA 1.5PRB; abdominal aoria: MA3PSB; common iliac artery: 2SB2 1 05; Transonic 
Systems Inc., USA) was placed on each blood vessel (Figure 3). The abdominal aorta 
flow probe was placed inferior to the left renal vasculature, superior to the remaining 
polypropylene suture. A thermometer was inserted into the rectum and the animal's 
temperature (35-38 °C) was maintained by adjusting heating lamps. The abdominal 
incision was covered with wet gauze before allowing the rat to stabi lize for fifty minutes. 
2.3. Continuous recording ofhaemodynamic parameters 
Arterial blood flows and pressure were continuously recorded in AcqKnowledge 
3.9. 1.6, which simultaneously calculated heart rate from the variations in arierial 
pressure. Equipment setup was similar to that of Guo and Tabrizchi (2008). Specifically, 
arterial pressure was recorded from the right external iliac artery with a pressure 
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Superior mesenteric artery 
Renal artery 
Abdominal aorta 
Site of aortic pu net ure 
Inferior vena cava 
Common iliac artery 
Figure 3. Flow probe placement and the site of aortic puncture. 
Blood flow was measured in the left renal artery, the superior mesenteric artery, the abdominal aorta, and the left common iliac 
artery. 
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transducer (P23XL, Spectramed Statham, USA) and the signal was then amplified (OA 
I OOA, Biopac Systems Inc. , USA). Transit-time perivascular flowmeters (TI 06 and 
T403, Transonic Systems Inc., USA) recorded arterial blood flows (review: Tabrizchi and 
Pugsley, 2000). Both the amplified pressure signal and the flowmeter signals were passed 
through a universal interface module (UIM I 00, Biopac Systems Inc., USA) into an 
acquisition unit (MP I 00, Biopac Systems Inc., USA), and the output signal was 
converted from analog to digital (USB I W, Biopac Systems Inc. , USA) before registering 
in AcqKnowledge 3.9.I.6. 
2.4. Experimental protocols 
The aortocaval fistu lae and sham-operated groups of rats were further divided into 
four treatment subgroups: captopril (an angiotensin-converting enzyme inhibitor), 
losartan (an AT 1 receptor antagonist) , PO I23319 (an AT2 receptor antagonist), and 
normal saline (the solvent in each of the other subgroups). 
Following a ten-minute baseline recording, four doses of either: captopril (0 .3, 
1.0, 3.0, IO mg/kg), losatian (2.5, 5.0, 10, 20 mg/kg), PO 1233 I9 (O.I, 0.3, 1.0, 3.0 
mg/kg), or normal sali ne (67, 200, 67, 200 IlL/kg), were administered intravenously at 
approximately twenty-minute intervals (Figure 4; Tabrizchi and Lupichuk, 1995; Scheuer 
and Perrone, I993; Stromberg et al. , I993). Normal saline injections were volume-
matched to those of PD 123319, the largest volumes injected. Upon completion, rats were 
euthanized by intravenous injection of saturated potassium chloride (3 mL). The heart 
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perivascular flow probes, and a 
rectal thermometer. 
Figure 4. Timeline of experimental protocols. 
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(left ventricle and septum separated from the right ventricular wall) was weighed, dried 
for six hours (59-61 °C), and then weighed again. 
2.5. Data measurements and calculations 
Baseline values of continuously recorded blood flows, pressures, and calculated 
hea1i rates were measured as the average of the five minutes immediately preceding the 
first dose of treatment. Post-dose values of the same parameters were measured as the 
average of the four minutes immediately preceding the next dose of treatment, stmiing 
approximately sixteen minutes after administration of the preceding dose. Arterial 
conductance was calculated for each blood vessel (flow/mean arterial pressure measured 
in the external iliac artery; Lautt, 1988). Arterial pressure has been shown to vary 
between 5-6 mmHg in different arteries; therefore an inherent error is associated with 
each calculation of conductance, as the arterial pressure in each individual blood vessel 
was not recorded (Pang and Chan, 1985). However, it would not be feasible to measure 
blood flow and pressure in the same blood vessel at the same time, as the instrumentation 
required to measure one parameter may affect the other parameter. 
To normalize the data, change from baseline was calculated for haemodynamic 
parameters by subtracting baseline values from post-dose values. Initial analysis by two-
way analysis of variance with repeated measures indicated that the vehicle/time effects in 
rats with and without aortocaval fistulae differed with respect to mean arterial pressure 
and superior mesenteric blood flow. To allow for direct comparison of treatment effects 
between the groups, corrected changes from baseline were calculated for haemodynamic 
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parameters. In parallel, the mean change from baseline of the saline rats at each saline 
injection was subtracted from the respective change from baseline of each drug-treated 
rat within the same group (sham-operated and aortocaval fistulae rats). 
All data are presented as a mean ± the standard error of the mean, and the number 
of animals (n). All graphs were prepared in SigmaPlot 8.0 (SPSS Inc., USA). 
2.6. Statistical analyses 
Baseline values of arterial flows, arterial conductances, mean arterial pressure and 
heart rate were compared between the sham-operated and the aortocaval fistulae groups 
of rats by unpaired two-tailed Student's t-tests. Similarly, ventricular weights were 
compared between sham-operated and aortocaval fistulae rats by unpaired two-tai led 
Student's t-tests. Rat weights (initial, weekly, experiment), were compared between the 
sham-operated and the aortocaval fistu lae groups of rats by two-way analysis of variance 
with repeated measures. Baseline haemodynamic values were used to determine 
subgroup homogeneity within the sham-operated group of rats and wi thin the aortocaval 
fistulae group of rats by one-way analysis of variance. 
Change from baseline was used to compare the effects of captopril , losartan and 
PD 123319 to that of normal saline within the sham-operated group of rats and within the 
aortocaval fistulae group of rats, by two-way analysis of variance with repeated 
measures. Similarly, the change from baseline in haemodynamic parameters of both 
normal saline subgroups were compared by two-way analysis of variance with repeated 
measures. 
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Corrected change from baseline was used to compare treatment effects between 
the sham-operated and the aortocaval fistulae groups of rats, and between drug treatments 
within each group of rats , by two-way analysis of variance with repeated measures. 
All statistical analyses were completed in SigmaStat 3. 10.0 (Systat Software Inc. , 
USA), p<0.05 was considered significant for all statistical analyses. When statistically 
significant differences were detected by analysis of variance, the Holm-Sidak method 
was used for correction of multiple comparisons testing. 
2.7. Data exclusion 
Seventy experimental protocols were successfully completed; however, six of 
these were excluded from the final analysis for the fo llowing reasons: (1) high baseline 
renal blood flow in a sham-operated rat (excluded: 17.2 mL!min, remaining: 8.3 ± 0.4 
mL/min, n=34), (2) low baseline mesenteric blood flow in a sham-operated rat (excluded: 
1.1 mL/min, remaining: 10.0 ± 0.5 mL!min, n=34), (3) low baseline mean arterial 
pressure in a sham-operated rat (excluded: 50 mmHg, remaining: 95 ± 3 mmHg, n=34), 
( 4) large increase in mesenteric blood flow upon administration of captopril in a rat with 
aortocaval fistula (excluded: + 13 .3 mL/min, remaining: + 1.6 ± 1.5 mL/min, n=6), (5) 
large decrease in mean arterial pressure upon administration of normal saline in a rat with 
a011ocaval fistula (excluded: -36 mmHg, remaining: 0 ± 4 mmHg, n=7), and (6) large 
increase in mean arterial pressure upon administration of normal saline in a sham-
operated rat (excluded : +25 mmHg, remaining: -1 2 ± 3 mmHg, n= l O) . 
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2.8. Fine chemicals 
Isoflurane was purchased from CDMV (Canada). Heparin sodium was obtained 
from SoloPak Laboratories Inc. (USA) and Sigma-Aldrich Inc. (USA). Sigma-Aldrich 
Inc. (USA) also supplied bupivacaine hydrochloride, buprenorphine hydrochloride, 
captopril, and thiobutabarbital sodium. PD 123319 ditrifluoroacetate was purchased from 
Tocris Bioscience (UK), and losartan potassium was donated by DuPont Merck 
Pharmaceutical Company (USA). 
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3. Results 
3.1 . Body weights and ventricular weights 
Sham-operated and aortocaval fistulae rats had similar weekly body weights 
following fistula formation, and similar body weights at the time of experimentation. The 
left ventricle and septum and right ventricle of rats with aortocaval fistulae were 
significantly heavier than those of sham-operated rats when either the wet or the dry 
weights were compared (Table 3). However, the ratios of left ventricle and septum to 
right ventricle were similar between rats with and without aortocaval fi stulae when 
calculated using either wet or dry weights. 
3.2. Baseline haemodynamic values 
Sham-operated and aortocaval fistulae rats were similar with respect to baseline 
mean arterial pressure (MAP) and heart rate (HR; Figure 5AB). However, aortic blood 
flow and conductance (ABF, AC) were significantly higher, while the mesenteric and 
renal blood flows and conductances (MBF, RBF, MC, RC) were significantly lower, in 
rats with aortocaval fistulae compared to sham-operated rats (Figure 6ABCD). Iliac blood 
flow and conductance (IBF) was similar in both groups. 
3.3. Baseline haemodynamic values by treatment group 
Recorded and calculated baseline values were analyzed to ensure similar values 
amongst the treatment groups of sham-operated rats, and amongst the treatment groups of 
rats with aortocaval fistulae (Tables 4 and 5). Baseline values of treatment groups were 
53 
Table 3. Ventricular hypertrophy in rats with aortocaval fi stulae. 
Weights (g) and ratios of wet or dry ventricles of sham-operated and aortocaval fistulae rats. Values are mean ± SEM. LV+S: 
left ventricle and septum; RV : right ventricle. 
*significantly different from the respective sham value 
Group n 
Wet Dry 
LV+S RV LV+S/RV ratio LV+S RV LV+S/RV ratio 
Sham 34 0.8 1 ± 0.01 0.28 ± 0.01 2.96 ± 0.06 0.29 ± 0.01 0.08 ± 0.01 3.83 ± 0.1 3 
Fistula 30 1.16 ± 0.03 * 0.52 ± 0.07* 2.66 ± 0.18 0.49 ± 0.03 * 0.13 ± 0.0 1 * 3.9 1 ± 0.19 
54 
A B 
120 
• 
4 50 I • I I I 400 I • 100 I I I I 350 
80 I 300 I I 0'> ~ I I I 250 E a_ 
_§_ 60 I ~ 
a_ 
• 
a: 200 
<l: I 
~ 
40 150 
100 
20 
50 
0 0 
Sham Fistula Sham Fistu la 
Figure 5. Baseline mean arterial pressures and heart rates of anaesthetized rats five weeks after sham or fistula surgery. 
Sham-operated rats: MAP=95±3 mmHg, HR=362±8 BPM, n=34; rats with aortocaval fistulae: MAP=88±3 mmHg, 
HR=362± 7, n=30. MAP: mean arterial pressure; HR: heart rate. 
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Figure 6. Baseline blood flows and conductances of anaesthetized rats five weeks after sham or fi stula surgery. 
All conductances were calculated using mean arterial pressure measured in the external iliac artery. Values are mean ± SEM. 
Sham-operated rats, n=34; rats with aortocaval fistulae, n=JO. Q: blood flow; G: vascular conductance. 
*significantly different from the sham group, p<O.OS 
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Table 4. Baseline heart rate, mean arterial pressure, and blood flows in rats with and without aortocaval fi stulae. 
Values are mean ± SEM. HR: heart rate; MAP: mean arterial pressure. 
*significantly different from sham-operated captopril and saline, p<O.OS 
MAP Blood Flows 
Group Subgroup HR (external iliac (mL x min-
1) 
n (BPM) artery; 
mmHg) Aortic Mesenteric Renal Iliac 
Sham-Operated Saline 10 347 ± 12 101 ± 2 10.4 ± 1.6 12.4 ± 0.7 9.2 ± 0.8 2.3 ± 0.4 
Captopril 7 372 ± 16 98 ± 3 10.9 ± 1.3 11.9 ± 1.1 9.4 ± 0 .7 2.8 ± 0.4 
Losartan 9 374 ± 13 97 ± 6 9.7 ± 1.3 8.0 ± 0.5* 8.0 ± 0.6 3.4 ± 0.8 
PD 123319 8 360 ± 20 81 ± 9 9.5 ± 1.4 7.8 ± 0.4* 6.6 ± 0.8 3.0 ± 0.4 
Aortocaval Saline 7 377 ± 17 86 ± 7 119 ± 14 7.2 ± 1.1 5.3 ± 0.9 2.8 ± 0.4 
Fistula Captopril 6 348 ± 21 83 ± 4 155 ± 11 5.9 ± 0.7 4.6 ± 0.4 3.2 ± 0.6 
Losartan 9 356 ± 12 97 ± 6 139 ± 20 7.3 ± 0.8 6.1 ± 0.6 2.3 ± 0.4 
PD 123319 8 368 ± 8 81 ± 9 130 ± 12 6.1 ± 0.6 4.8 ± 0.5 2.0 ± 0.3 
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Table 5. Baseline regional vascular conductances in rats with and without aortocaval fistu lae. 
All conductances were calculated using mean arterial pressure measured in the external iliac artery. Values are mean ± SEM . 
• 
significantly different from sham-operated captopril and saline, p<O.OS 
- I - I 
G roup Subgroup 
Conductance (mL x min x mmHg) 
n 
Aortic Mesenteric Renal Iliac 
Sham -Operated Saline 10 0.10 ± 0.02 0.12 ± 0.01 0.09 ± 0.01 0.02 ± 0.00 
Captopril 7 0.12 ± 0.01 0.12 ± 0.01 0.10 ± 0.01 0.03 ± 0.01 
Losartan 9 0.10 ± 0.02 o.o8 ± o.o1 · 0.08 ± 0.01 0.03 ± 0.01 
PD 123319 8 0.12 ± 0.0 1 0.10 ± 0.01 0.08 ± 0.01 0.04 ± 0.01 
Aortocaval Saline 7 1.4±0.2 0.08 ± 0.01 0.06 ± 0.01 0.03 ± 0.01 
Fistula Captopril 6 1.9±0.1 0.07 ± 0.01 0.06 ± 0.01 0.04 ± 0.01 
Losartan 9 1.5 ± 0.2 0.08 ± 0.01 0.06 ± 0.00 0.03 ± 0.00 
PD 123319 8 1.6 ± 0.1 0.07 ± 0.01 0.06 ± 0.01 0.02 ± 0.00 
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not compared between sham-operated rats and rats with aotiocaval fistulae because 
treatment effects were compared as changes from baseline. The MBF of the captopril and 
normal saline treatment groups of sham-operated rats were significantly greater than 
those of the losartan and PD 123319 treatment groups. Furthermore, the MC of the 
captopril and normal saline treatment groups were significantly greater than that of the 
losartan treatment group. No statistical differences in baseline values were detected 
amongst the treatment groups of rats with aortocaval fistulae. 
3.4. Comparison of captopril, losartan, and PD 123319 to normal saline in sham-operated 
rats 
PD 123319 significantly increased mean atierial pressure (6MAP), whereas the 
reductions by captopril and losartan were similar to that of the normal saline group 
(Figure 7 A). The changes in heart rate (6HR) produced by captopril, losartan, and PD 
123 319 were similar to that of the normal saline group, although increasing doses of 
captopril tended to decrease 6HR (Figure 7B). 
The changes in: aortic blood flow (6ABF), mesenteric blood flow (6MBF), renal 
blood flow (6RBF), and iliac blood flow (6IBF) produced by captopri l, losartan, and PD 
123319 were similar to those of the normal saline group (Figure 8ABCD). However, 
captopril, losartan, and PD 123319 tended to increase 6MBF, whereas a time-dependent 
decrease in 6MBF was observed in the normal saline group. 
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Figure 7. Changes in mean arterial pressure and heart rate due to drug treatments in sham-operated rats. 
Changes in mean arterial pressure and heart rate of anaesthetized rats were compared to the respective time-effects of saline 
administration. Doses were administered every twenty minutes following the control measurement to which subsequent 
measurements were normalized. Values are mean ± SEM. Captopri l: 0.3 , 1.0, 3.0, 10.0 mg/kg, n=7; losartan: 2.5, 5.0, 10.0, 
20.0 mg/kg, n=9; PD 1233 19:0.1 , 0.3 , 1.0, 3.0 mg/kg, n=8, saline: 67,200, 67,200 j..tL/kg, n= 10. SO: sham-operated; LIMAP: 
change in mean arterial pressure; LIHR: change in heart rate; Dl: dose 1; D2: dose 2; D3 : dose 3; D4: dose 4. 
*significantly different from the saline group, p<0.05 
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Figure 8. Changes in blood flows due to drug treatments in sham-operated rats. 
Changes in blood flows of anaesthetized rats were compared to the respective time-effects of saline administration. Doses were 
administered every twenty minutes following the control measurement to which subsequent measurements were normalized. 
Values are mean ± SEM. Captopril: 0.3 , 1.0, 3.0, 10.0 mg/kg, n=7; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg, n=9; PO 123319: 0.1 , 
0.3, 1.0, 3.0 mg/kg, n=8, saline: 67, 200, 67, 200 ).!Likg, n=1 0. SO: sham-operated; LIQ: change in blood flow; 01: dose 1; 02: 
dose 2; D3: dose 3; 04: dose 4. 
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A time-dependent decrease in aortic conductance (6AC) was observed in the 
normal saline group (Figure 9A). Captopril and losartan suppressed the time-dependent 
decrease, whereas PD 1233 19 augmented the decrease. However, the 6AC produced by 
captopril, losartan, and PD 123319 were similar to that of the normal saline group. In 
contrast, captopril and losartan significantly increased mesenteric conductance (6MC) 
compared to the normal saline group (Figure 9B). The decrease in 6MC produced by PD 
123319 was not significantly different from the nonnal saline group. Additionally, 
captopril and losartan caused significant increases in renal conductance (6RC) compared 
to the normal saline group (Figure 9C). In contrast, PD 1233 19 caused a significant 
decrease in 6RC. PD 12331 9 significantly decreased iliac conductance (6IC) compared 
to normal saline, while captopril and losartan had no effect on 6 IC (Figure 9D). 
3.5. Comparison of captopril, losartan, and PD 1233 19 to normal sal ine in rats with 
aortocaval fistulae 
Captopril and losartan had significant dose-dependent hypotensive effects when 
compared to the normal saline group (Figure lOA). In contrast, PD 1233 19 had no 
significant effect on 6MAP. The 6HR were similar between the captopril , losartan, and 
PD 1233 19 groups and the normal saline group (Figure 1 OB). 
Captopril and losarian caused significant dose-dependent decreases in 6ABF 
compared to the normal saline group, whereas the decrease produced by PD 123319 was 
not significant (Figure 11 A). In contrast, losartan caused a significant dose-dependent 
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Figure 9. Changes in vascular conductances due to drug treatments in sham-operated rats. 
Changes in vascular conductances of anaesthetized rats were compared to the respective time-effects of saline administration. 
Doses were administered every twenty minutes following the control measurement to which subsequent measurements were 
normalized. All conductances were calculated using mean arterial pressure measured in the external iliac artery. Values are 
mean ± SEM. Captopril: 0.3 , 1.0, 3.0, 10.0 mg/kg, n=7; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg, n=9; PD 123319:0.1 , 0.3, 1.0, 3.0 
mg/kg, n=8, saline: 67, 200, 67, 200 )..LLikg, n=10. SO: sham-operated; LJG: change in vascular conductance; Dl: dose 1; D2: 
dose 2; D3: dose 3; D4: dose 4. 
*significantly different from the saline group, p<0.05 
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Figure 10. Changes in mean arterial pressure and heart rate due to drug treatments in rats with aortocaval fistulae. 
Changes in mean arterial pressure and heart rate of anaesthetized rats were compared to the respective time-effects of saline 
administration. Doses were administered every twenty minutes fo llowing the control measurement to which subsequent 
measurements were normalized. Values are mean ± SEM. Captopril: 0.3 , LO, 3.0, 10.0 mg/kg, n=6; losartan: 2.5, 5.0, 10.0, 
20.0 mg/kg, n=9; PD 1233 19: 0.1 , 0.3, 1.0, 3.0 mg/kg, n=8, saline: 67, 200, 67, 200 ).!Likg, n=7. ACF: aortocaval fistulae; 
L1 MAP: change in mean arterial pressure; L1HR: change in heart rate; Dl: dose 1; D2: dose 2; D3: dose 3; D4: dose 4. 
*significantly different from the saline group, p<0.05 
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Figure 11 . Changes in blood flows due to drug treatments in rats with aortocaval fistulae. 
Changes in blood flows of anaesthetized rats were compared to the respective time-effects of saline administration. Doses were 
administered every twenty minutes following the control measurement to which subsequent measurements were normalized. 
Values are mean ± SEM. Captopril: 0.3, 1.0, 3.0, 10.0 mg/kg, n=6; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg, n=9; PD 1233 19: 0.1, 
0.3, 1.0, 3.0 mg/kg, n=8, saline: 67, 200, 67, 200 J.!Likg, n=7. ACF: aortocaval fistulae; LIQ: change in blood flow; Dl: dose 1; 
D2: dose 2; D3: dose 3; D4: dose 4. 
*significantly different from the saline group, p<0.05 
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increase in 6MBF, while the increases produced by captopril and PD 123319 were not 
significantly different from the normal saline group (Figure 11 B). The 6RBF and 6IBF 
produced by captopril, losartan, and PD 123319 were not significantly different from 
those of the normal saline group (Figure 11 CD). 
Losartan caused a significant dose-dependent increase in 6AC compared to the 
normal saline group (Figure 12A). The increase in 6AC produced by captopril and the 
variable effect of PD 123319 were not significantly different from the normal saline 
group. Captopril and losartan caused significant dose-dependent increases in 6MC 
compared to the normal saline group, while PD 1233 19 had little effect (Figure 12B). 
Losartan caused a significant dose-dependent increase in 6RC compared to the normal 
saline group, while neither captopril nor PD 1233 19 produced a significant effect (Figure 
12C). 6IC was not significantly affected by captopril, losartan, or PD 123319, when 
compared to the normal saline group (Figure 12D). 
3 .6. Comparison of the time effects in sham-operated and aortocaval fistu lae rats 
The time-dependent hypotensive effect of normal saline in sham-operated rats 
was significantly different from the variable 6MAP of rats with aortocaval fistulae 
(Figure 13A). The 6HR ofboth groups were similar (Figure 13B). 
The 6ABF of both normal saline-treated groups of rats were not significantly 
different (Figure 14A). In contrast, the increase in 6MBF in rats with aortocaval fistulae 
was significantly different from the time-dependent decrease in sham-operated rats 
(Figure 14B). The normal saline-treated groups ofrats had similar 6RBF and 6IBF 
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Figure 12. Changes in vascular conductances due to drug treatments in rats with aortocaval fistulae. 
Changes in regional vascular conductances of anaesthetized rats were compared to the respective time-effects of saline 
administration. Doses were administered every twenty minutes following the control measurement to which subsequent 
measurements were normalized. All conductances were calculated using mean arterial pressure measured in the external iliac 
artery. Values are mean ± SEM. Captopril: 0.3, 1.0, 3.0, 10.0 mg/kg, n=6; losartan: 2 .5, 5.0, 10.0, 20.0 mg/kg, n=9; PD 
123319: 0.1 , 0.3 , 1.0, 3.0 mg/kg, n=8, Saline: 67, 200, 67, 200 ).!Likg, n=7. ACF: aortocaval fistulae; LIG: change in vascular 
conductance; D 1: dose 1; D2: dose 2; 03: dose 3; D4: dose 4. 
*significantly different from the saline group, p<0.05 
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Figure 13. Changes in mean arterial pressure and heart rate due to saline treatment in rats with and without aortocaval fistulae. 
Volumes equivalent to the largest drug injections were administered to anaesthetized rats every twenty minutes following the 
control measurement to which subsequent measurements were normalized. Values are mean ± SEM. Saline: 67, 200, 67, 200 
)lLikg; sham-operated rats: n=1 0; rats with aortocaval fistulae : n=7. LIMAP: change in mean arterial pressure; LIHR: change in 
heart rate; Dl: dose 1; D2: dose 2; D3 : dose 3; D4: dose 4. 
*significantly different from the sham-operated group, p<0.05 
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Figure 14. Changes in blood flows due to saline treatment in rats with and without aortocaval fistulae. 
Volumes equivalent to the largest drug injections were administered to anaesthetized rats every twenty minutes following the 
control measurement to which subsequent measurements were normalized. Values are mean ± SEM. Saline: 67, 200, 67, 200 
J.!Likg; sham-operated rats : n=10; rats with aortocaval fistulae: n=7. L1 Q: change in blood flow; 01: dose 1; 02: dose 2; 0 3: 
dose 3; 04: dose 4. 
*significantly different from the sham-operated group, p<0.05 
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(Figure 14CO). Also, both groups of normal saline-treated rats experienced similar 
changes in vascular conductances (6AC, 6MC, 6RC, and 6IC; Figure 15ABCO). 
3. 7. Comparison of the effects of captopril, losartan. and PO 123 319 on mean arterial 
pressure and heart rate 
The dose-dependent hypotensive effects of captopril and losartan were 
significantly different from the hypertensive effect of PO 123319 in sham-operated rats 
(Figure 16A). Similarly, in rats with aortocaval fistulae, the hypotensive effects of 
captopril and losatian were significantly greater that the decrease in conected mean 
arterial pressure ( c6MAP) caused by PO 123319 (Figure 16B). When compared between 
the two groups, the hypotensive effect of losatian was significantly greater in rats wi th 
aortocaval fistulae than in sham-operated rats. Similarly, the hypotensive effect or PD 
123 319 in rats with aortocaval fistulae was significantly different from the pressor effect 
observed in sham-operated rats. 
The change in corrected heart rate (c6HR) produced by captopril , losatian, and 
PO 123319 were simi lar in sham-operated rats and in rats with aortocaval fistulae (Figure 
16CO). However, the increase in c6HR of rats with aortocaval fistulae treated with 
captopril was significantly different from the dose-dependent decrease in c6HR observed 
in sham-operated rats. 
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Figure 15. Changes in vascular conductances due to saline treatment in rats with and without aortocaval fistulae. 
Volumes equivalent to the largest drug injections were administered to anaesthetized rats every twenty minutes following the 
control measurement to which subsequent measurements were normalized. All conductances were calculated using mean 
arterial pressure measured in the external iliac artery. Values are mean ± SEM. Saline: 67, 200, 67, 200 )lLikg; sham-operated 
rats: n= 10; rats with aortocaval fistulae: n=7. LJ G: change in vascular conductance; Dl: dose 1; D2: dose 2; D3 : dose 3; D4: 
dose 4. 
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Figure 16. Changes in mean arterial pressure and heart rate due to drug treatments in rats with and without aortocaval fistulae. 
Doses were administered every twenty minutes following the control measurement to which subsequent measurements were 
normalized. Values are mean ± SEM. Captopril: 0.3 , 1.0, 3.0, 10.0 mg/kg; losartan: 2.5 , 5.0, 1 0.0, 20.0 mg/kg; PO 123319: 0.1, 
0.3, 1.0, 3.0 mg/kg; sham-operated rats: n=7 (captopril), 9 (losartan), 8 (PO 123319); rats with aortocaval fistulae: n=6 
(captopri l), 9 (losartan), 8 (PD 123319). SO: sham-operated; L1 MAP: change in mean arterial pressure; L1 HR: change in heart 
rate; 01: dose 1; 02: dose 2; D3: dose 3; 04: dose 4. 
asignificantly different from the PO 1233 19 group at the same dose time, p<0.05 
*significantly different from the respective sham value, p<0.05 
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3.8. Comparison of the effects of captopril, losartan, and PD 123319 on aortic blood flow 
and conductance 
In sham-operated rats, the decreases in corrected aortic blood flow ( cf..ABF) 
produced by captopril and losartan were similar to the increase in cf..ABF produced by 
PD 123319 (Figure 17 A). In rats with aortocaval fistulae, the dose-dependent decrease in 
cf..ABF produced by captopril was significantly greater than that produced by PD 123319 
(Figure 17B). The decreases in cf..ABF produced by captopril and losartan were 
significantly greater in rats with aortocaval fistulae than in sham-operated rats. Similarly, 
the decrease in cf..ABF produced by PD 123319 in rats with aortocaval fistulae was 
significantly different from the increase in cf..ABF in sham-operated rats. 
In sham-operated rats, the increases in corrected aortic conductance (cf..AC) 
produced by captopril and losartan were not significantly different from the decrease in 
cf..AC produced by PD 123319 (Figure 17C). In rats with aortocaval fistulae, the increase 
in cf..AC produced by losartan was significantly different from the variable effect of PD 
123319 on cf..AC (Figure 17D). However, the increase in cf..AC produced by captopril 
was similar to both the effects of losartan and PD 1233 19. Captopril and losartan 
increased cf..AC significantly more in rats with aortocaval fistulae than in sham-operated 
rats. The decreases produced by PD 123 319 were similar in both groups. 
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Figure 17. Changes in aortic blood flow and conductance due to drug treatments in rats with and without aortocaval fistulae. 
Doses were administered every twenty minutes following the control measurement to which subsequent measurements were 
normalized. All conductances were calculated using mean arterial pressure measured in the external iliac artery. Values are 
mean ± SEM. Captopril : 0.3 , 1.0, 3.0, 10.0 mg/kg; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg; PO 123319: 0.1 , 0.3, 1.0, 3.0 mg/kg; 
sham-operated rats: n=7 ( captopril), 9 (losartan), 8 (PD 123319); rats with aortocaval fistulae: n=6 ( captopril), 9 (losartan), 8 
(PO 123319). SO: sham-operated; LJQ: change in blood flow; 01: dose 1; 0 2: dose 2; 0 3: dose 3; 04: dose 4. 
asignificantly different from the PO 123319 group at the same dose time, p<0.05 
*significantly different from the respective sham value, p<0.05 
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3.9. Comparison of the effects ofcaptopril, losartan, and PD 123319 on mesenteric blood 
flow and conductance 
Captopril, losartan, and PD 123319 increased corrected mesenteric blood flow 
( c,6.MBF) to similar extents in sham-operated rats (Figure 18A). In rats with aortocaval 
fistulae, the dose-dependent increase in c,6.MBF produced by losartan was significantly 
different from the decrease in c,6.MBF produced by PD 123319 (Figure 18B). Captopril 
increased cl1MBF in rats with aotiocaval fistulae, this was not significantly different from 
the effects oflosmian or PD 123319. The decrease in c,6.MBF produced by PD 123319 in 
rats with aortocaval fistulae was significantly different from the increase in c,6.MBF in 
sham-operated rats. The increases in cl1MBF produced by captopril and losartan were 
similar between rats with and without a01iocaval fistulae. 
In sham-operated rats and in those with aortocaval fistulae, the dose-dependent 
increases in corrected mesenteric conductance (c,6.MC) produced by captopril and 
losartan were significantly different from the decrease in c,6.MC produced by PD 123319 
(Figure 18CD). The increase in cl1MC produced by losartan was significantly larger in 
rats with aortocaval fistulae than in sham-operated rats, while the effects of captopril and 
PD 1233 19 were similar in both groups. 
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Figure 18. Changes in mesenteric blood flow and conductance due to drug treatments in rats with and without aortocaval 
fistulae. Doses were administered every twenty minutes following the control measurement to which subsequent 
measurements were normalized. All conductances were calculated using mean arterial pressure measured in the external iliac 
artery. Values are mean ± SEM. Captopril: 0.3, 1.0, 3.0, 10.0 mg/kg; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg; PD 123319: 0.1, 0.3, 
1.0, 3.0 mg/kg; sham-operated rats: n=7 ( captopril), 9 (losartan), 8 (PO 123319); rats with aortocaval fistulae: n=6 ( captopril), 
9 (losartan), 8 (PD 123319). SO: sham-operated; LJG: change in vascular conductance; 01: dose 1; D2: dose 2; D3: dose 3; D4: 
dose 4. 
asignificantly different from the PO 123319 group at the same dose time, p<0.05 
*significantly different from the respective sham value, p<0.05 
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3.1 0. Comparison of the effects of captopril, losartan, and PD 123319 on renal blood flow 
and conductance 
In sham-operated rats, captopril and losartan had variable effects on corrected 
renal blood flow (c6RBF) that were not significantly different from the increase in 
c6RBF produced by PD 123319 (Figure 19A). In contrast, the increase in c6RBF 
produced by losartan was significantly different from the decreases in c6RBF produced 
by captopril and PD 12331 9 in rats with aOiiocaval fistulae (Figure 19B). The decrease in 
c6RBF produced by PD 123319 and the increase produced by losartan in rats with 
aortocaval fistulae were significantly different from the variable effects of losartan and 
the increase produced by PD 123 319 in sham-operated rats. 
In sham-operated rats, the increases in corrected renal conductance ( c6RC) 
produced by captopril and losartan were significantly different from the decrease in 
c6RC produced by PD 1233 19 (Figure 19C). However, the increase in c6RC produced 
by losartan in rats with aortocaval fistulae was significantly different from the smaller 
increase in c6RC produced by captopril and the decrease in c6RC caused by PD 123 3 19 
(Figure 19D). The decrease in c6RC produced by PD 123319 in rats with aortocaval 
fistulae was significantly smaller than the decrease in c6RC produced by PD 123 319 in 
sham-operated rats. In contrast, the increases in c6RC produced by captopril and losartan 
were similar between rats with and without aortocaval fi stulae. 
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Figure 19. Changes in renal blood flow and conductance due to drug treatments in rats with and without aortocaval fistulae. 
Doses were administered every twenty minutes following the control measurement to which subsequent measurements were 
normalized. All conductances were calculated using mean arterial pressure measured in the external iliac artery. Values are 
mean ± SEM. Captopril: 0.3 , 1.0, 3.0, 10.0 mg/kg; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg; PD 123319: 0.1 , 0.3, 1.0, 3.0 mg/kg; 
sham-operated rats: n=7 ( captopril), 9 (losartan), 8 (PD 123319); rats with aortocaval fistulae: n=6 ( captopril), 9 (losartan), 8 
(PD 123319). SO: sham-operated; LJQ: change in blood flow; Dl: dose 1; D2: dose 2; D3: dose 3; D4: dose 4. 
3 significantly different from the PD 123319 group at the same dose time, p<0.05 
bsignificantly different from the captopril and PD 123319 groups at the same dose time, p<0.05 
*significantly different from the respective sham value, p<0.05 
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3.11. Comparison ofthe effects ofcaptopril, losartan, and PD 1233 19 on iliac blood flow 
and conductance 
The variable effects of captopril and PD 123319 on corrected iliac blood flow 
(c.t.IBF) were not significantly different from the decrease in c.t.IBF produced by losartan 
in sham-operated rats (Figure 20A). Similarly, the decreases in c.t.IBF produced by 
captopril, losartan, and PD 123319 were similar in rats with aortocaval fistulae (Figure 
20B). Furthermore, the effects of captopril, losartan, and PD 1233 19 were similar 
between rats with and without aortocaval fistulae. 
In sham-operated rats, the increase in corrected iliac conductance (c.t.IC) 
produced by captopril was significantly different from the dose-dependent decrease in 
c.t.IC produced by PD 1233 19 (Figure 20C). Similarly, the increase in c.t.IC produced by 
losartan was significantly different from the decrease in c.t.IC produced by PD 123319 in 
rats with aortocaval fistulae (Figure 20D). The effects of captopril , losartan, and PD 
1233 19 were similar between rats with and without ao1iocaval fistulae. 
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Figure 20. Changes in iliac blood flow and conductance due to drug treatments in rats with and without aortocaval fistulae. 
Doses were administered every twenty minutes following the control measurement to which subsequent measurements were 
normalized. All conductances were calculated using mean arterial pressure measured in the external iliac artery. Values are 
mean ± SEM. Captopril: 0.3 , 1.0, 3.0, 10.0 mg/kg; losartan: 2.5, 5.0, 10.0, 20.0 mg/kg; PD 123319: 0.1 , 0.3, 1.0, 3.0 mg/kg; 
sham-operated rats: n=7 ( captopril), 9 (losartan), 8 (PD 123319); rats with aortocaval fistulae: n=6 ( captopril), 9 (losartan), 8 
(PD 123319). SO: sham-operated; L1Q: change in blood flow; D1: dose 1; D2: dose 2; D3: dose 3; D4: dose 4. 
3 significantly different from the PD 1233 19 group at the same dose time, p<0.05 
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4. Discussion 
We hypothesized that the RAAS has a greater influence over blood flow 
distribution in rats with aortocaval fistulae than in sham-operated rats. To test this 
hypothesis, changes in regional blood flows and conductances produced by captopril, 
losartan, and PD 123319 were compared between these two groups of rats. Overall, the 
results of this study suggest that Ang II is more active in the continuous control of 
regional haemodynamics in rats with aortocaval fistulae than in sham-operated rats. 
We also hypothesized that the increases in regional blood flows and conductances 
produced by AT 1 receptor antagonism would be larger than the decreases produced by 
AT2 receptor antagonism, in rats with and without aortocaval fistulae. To test this 
hypothesis, changes in regional blood flows and conductances produced by losartan and 
PD 123319 were compared within each group of rats. The results suggest that AT 1 
receptors are more active than A T2 receptors in the continuous control of regional 
haemodynamics in rats with aortocaval fistulae. In contrast, the continuous control of 
regional haemodynamics by AT1 and AT2 receptors in sham-operated rats is regionally 
specific. 
The results of this study suggest that the activated RAAS of rats with aortocaval 
fistulae has a greater influence in controlling regional haemodynamics than in sham-
operated rats. Furthermore, the RAAS is altered in rats with aotiocaval fistulae to favor 
vasoconstriction via AT 1 receptors, possibly as a mechanism of maintaining a normal 
mean arterial pressure despite a large decrease in total peripheral resistance. Although the 
experimental technique of this study cannot elucidate changes in AT1 and AT2 receptor 
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expression, the introduction of aortocaval fistulae likely causes a molecular change at the 
receptor level. For example, vasoconstriction might be favored in rats with aortocaval 
fistulae by upregulation of AT 1 receptors and/or downregulation of AT 2 receptors. 
4.1. Ang II control of regional haemodynamics m rats with and without aortocaval 
fistulae 
Captopril caused similar changes in mean arterial pressure, regional blood flows 
and regional conductances in rats with and without aortocaval fistulae (Figures 158, 
1780, 1880, and 198D). This suggests that the continuous control of regional 
haemodynamics is similar between the two groups. However, the effects of activated AT 1 
and AT2 receptors generally oppose each other, and the dual attenuation of AT 1 and AT2 
receptor activation by ACE inhibitors could result in unchanged regional haemodynamics 
(review: Nguyen Oinh Cat and Touyz, 2011). 
This study has shown that AT 1 receptors exert a greater influence than AT 2 
receptors over regional haemodynamics in rats with aortocaval fistulae (Figures 1780, 
1880, and 190). In comparison, both receptors exert variable influence over regional 
haemodynamics in sham-operated rats (Figures 17C, 18C, and 19C). As such, ACE 
inhibition would be expected to result in vasodilation in rats with aortocaval fistulae by 
attenuation of AT 1 receptor activation. Similarly, attenuation of AT 1 receptor activation 
should cause vasodilation in sham-operated rats. However, the added attenuation of AT2 
receptor activation in these rats would negate some of the vasodi lation produced by 
attenuation of AT 1 receptor activation. Therefore, the changes in regional conductances 
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of rats with aortocaval fistulae was expected to be significantly larger than m sham-
operated rats. 
This hypothesis is inconsistent with the results that when treated with captopril 
the changes in all regional conductances were greater, although not significantly greater, 
in sham-operated rats than in rats with aotiocaval fistu lae (Figures l 7D, 18D, and 19D). 
However, AT1 receptor antagonism did produce the expected result of larger changes in 
all regional conductances in rats with aortocaval fistulae than in sham-operated rats, 
although this was only significant in the mesenteric bed (Figures 17D, 18D, and 19D). 
The upregulation of enzymes capable of ACE-independent Ang II production throughout 
the vasculature or suffic iently within a single region to produce systemic effects could 
explain the inabi lity of captopri l to modify regional conductance in rats with aortocaval 
fistulae. Enzymes capable of ACE-independent Ang II production are present in rat 
vascular beds and tissues; they appear to by upregulated in some rat models of 
hypertension (Santos et al. , 2003; Guo et al. , 200 1 ). 
Administration of losartan to rats with aortocaval fistu lae resulted in a 
significantly larger decrease in mean arterial pressure, and significantly larger increases 
in mesenteric conductance and renal blood flow, than in sham-operated rats (Figures 15B, 
17D, and 18B). This suggests that Ang II activation of AT 1 receptors exerts greater 
control over regional haemodynamics in rats with aortocaval fistu lae than in sham-
operated rats. 
In sham-operated rats, PD 1233 19 significantly increased mean arterial pressure, 
mesenteric blood flow, and renal blood flow, and sign ificantly decreased renal 
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conductance, compared to rats with a011ocaval fistulae (Figures 15B, 17B, and 18BD). 
This suggests that Ang II activation of AT2 receptors exerts greater control over regional 
haemodynamics in sham-operated rats than in rats with aortocaval fistulae. 
4.2. AT 1 and AT 2 receptor control of regional haemodynamics in rats with aortocaval 
fistulae 
In rats with aortocaval fistulae, losartan decreased mean arterial pressure more 
than PD 123319. Furthermore, losartan increased mesenteric, renal, and iliac 
conductances, whereas PD 123319 caused small decreases in these conductances (Figures 
15B, 16D, 18D, and 19D). These results suggest that AT 1 receptors exert a greater 
influence than AT2 receptors in the control of haemodynamics in rats with aortocaval 
fi stulae. Given the smaller effects of PD 1233 19 on mean arterial pressure and regional 
conductances, it would seem that Ang II activation of AT 2 receptors exerts little influence 
over regional haemodynamics in rats with aortocaval fistulae. 
However, losartan increased renal conductance significantly more than captopril , 
yet captopril and losartan yielded similar effects on mean arteria l pressure and mesenteric 
conductance (Figures 18D, 15B, and 17B). The observed lack of captopril-mediated 
alteration in renal conductance might be explained on a tissue rather than systemic level 
and seems to be related to the presence of aortocaval fistu lae, as losartan and captopril 
increased renal conductance similarly in sham-operated rats (Figure 19C). 
The attenuated effect of captopril on renal conductance in rats with aortocaval 
fistulae might indicate regionally specific upregulation of ACE-independent Ang II 
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production in rats with aortocaval fistulae (Figure 19D). Others have found increased 
ACE-independent Ang II production in the ischaemic kidneys of two-kidney one-clip rats 
and dogs (Sadjadi et a!., 2005; Tokuyama et a!. , 2002). The ACE-independent pathways 
of Ang II production were attributed to chymase or chymase-like activity, potentially that 
of elastase-2 (Santos eta!. , 2003 ; Guo eta!., 2001). Rats with aortocaval fistulae have a 
reduced renal blood flow, this specifically affects the renal cortex (Abassi et a!. , 1998a). 
If the renal ischaemia produced in rats with aortocaval fistulae results in renal 
upregulation of ACE-independent Ang II production, it would explain the attenuated 
renal effect of captopril compared to losartan. 
Alternatively, it is possible that antagonism of AT2 receptors is trivial compared 
to the effects of activated AT1 receptors. However, in the setting of AT 1 receptor 
antagonism, the AT2 receptors may play a large role in the observed renal vasodilation 
(Figure 19D). In this case, ACE inhibition would dually attenuate the activation of AT 1 
and AT2 receptors, and the vasodilatory actions of activated AT2 receptors would be null. 
Regardless, ACE inhibition may favor vasodilation by mechanisms other than attenuation 
of AT 1 receptor activation. 
ACE inhibition by captopril should simultaneously attenuate ACE-mediated 
bradykinin degradation and may result in increased Ang 1-9 production by ACE2 
produced by decreased substrate competition (review: Nguyen Dinh Cat and Touyz, 
2011 ; Kurdi eta!. , 2005). Ang 1-9 has been observed to potentiate bradykinin 8 2 receptor 
release ofNO, and therefore may contribute to captopril-mediated vasodilation (Jackman 
et al. , 2002). Finally, neprilysin can convert Ang I to Ang 1-7 (review: Ferrario et a!. , 
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1998). Ang 1-7 activation of Mas and AT2 receptors would result in further vasodilation 
during ACE inhibition by captopril (Ocaranza eta!., 2010; review: Rabelo eta!., 2011). 
4.3. AT1 and AT2 receptor control ofregional haemodynamics in sham-operated rats 
The increase in mean arterial pressure and decreases in mesenteric conductance 
and renal conductance produced by losartan, along with the opposing effects of PD 
123319 on these parameters, indicates that AT1 and AT2 receptors are continuously active 
in sham-operated rats (Figures 15A, 17C, and 18C). Yet, there appears to be no 
haemodynamic differences between captopril and losartan administration m sham-
operated rats (Figures 15A, 17 AC, 18AC, and 19AC). With ACE inhibition by captopril , 
the attenuation of AT 2 receptor activation, which should cause vasoconstriction, might be 
overshadowed by other vasodilatory mechanisms during ACE inhibition. 
The comparable decreases in mean arterial pressure, and increases in renal and 
mesenteric conductance, produced by captopril and losartan administration would seem 
to suggest that all Ang II effects are mediated by activation of AT1 receptors in sham-
operated rats (Figures 15A, 17C, and 18C). However, AT 2 receptor antagonism increased 
mean arterial pressure and decreased mesenteric, renal, and iliac conductances (Figures 
15A, 17C, 18C, and 19C). It appears that ACE inhibition produces functionally different 
effects than the sum of individual AT 1 and AT 2 receptor antagonism. Again, this may be 
explained by other vasodilatory mechanisms as consequences of ACE inhibition. 
Although drug treatments produced no change in blood flows, vascular 
conductances varied with drug treatment. Captopril and losartan increased mesenteric and 
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renal conductances, while PD 1233 19 decreased renal and hindquarter conductances 
(Figure 9BCD). These observations suggest that the mesenteric and renal vascular tones 
are continually controlled by activation of AT1 receptors in sham-operated rats. In 
contrast, A T2 receptor antagonism resulted in significant renal and hindquarter 
vasoconstriction. This suggests maintenance of renal and hindquarter vascular 
conductances by Ang II activation of AT2 receptors in sham-operated rats. However, it is 
particularly possible that the decrease in renal conductance was not a direct consequence 
of renal AT 2 receptor antagonism, but due to auto-regulatory responses to maintain 
normal blood flow despite increased mean arterial pressure produced by PD 123319 
antagonism of AT2 receptors (Hill et al. , 2010). 
It is perhaps surprising that captopril and losartan did not significantly decrease 
mean arterial pressure in sham-operated rats. This is likely because the decrease in mean 
arterial pressure was compared to the sizeable decrease produced by normal saline, and 
because the RAAS is not overtly activated in sham-operated rats (Figure 7 A). Similarly, 
Gonzalez-Perez et al. (1985) observed no significant change in femoral pressure when 
comparing the decrease produced by captopril (5 mg/kg) to normal saline injected rats. 
4.4. Ventricular hypertrophy in rats with aortocaval fistulae 
Similar to other studies, rats with aortocaval fistulae developed left and right 
ventricular hypertrophy (Guo and Tabrizchi, 2008; Willen brock et al. , 1999b ). The ratio 
of left to right ventricular weight was similar between the groups of rats (Table 3). This 
suggests that the left and right ventricles hypertrophied to similar extents. Liu et al. 
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(1991) measured increased left and right ventricular end diastolic pressures in rats with 
aortocaval fistulae. This might account for the elevated left ventricular end diastolic wall 
stress of rats with aortocaval fi stulae (Gladden et al., 2011 ; Hutchinson et al. , 2011 ). In 
volume overload, increased ventricular wall thickness and increased ventricular chamber 
size occur with increased left ventricular wall stress (Grossman eta!. , 1975). Enlargement 
of the ventricular chambers and thickening of ventricular walls reduces wall stress (Liu et 
a!. , 1991 ). Therefore, this study suggests that right ventricular wall stress is also 
increased, and that the left and right ventricles hypertrophied to similar extents to 
mitigate increased wall stress. 
4.5. The haemodynamic stability of rats with and without aortocaval fistulae 
The haemodynamic stability of rats with and without aortocaval fistulae differed 
with respect to mean arterial pressure and mesenteric blood flow, as assessed by normal 
saline injection (Figures 12A and 13B). Generally, rats with aotiocaval fistulae 
maintained both parameters at or above their baseline values, whereas time-dependent 
decreases in both parameters were observed in sham-operated rats. 
Guo and Tabrizchi (2008) observed no decrease in mean arterial pressure of 
sham-operated rats infused with normal saline. Given the similar preparation of rats with 
aortocaval fistulae, the different trends might be produced by experimental protocols. 
Guo and Tabrizchi (2008) inserted catheters into both iliac veins and arteries, as well as 
into the left ventricle and a balloon-tipped catheter into the right atrium. The additional 
instrumentation or the recurrent cessation of blood flow for measurement of mean 
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circulatory filling pressure might have resulted in activation of sympathetic responses 
that maintained mean arterial pressure. 
The presence of aortocaval fistulae may explain the ability of rats with aortocaval 
fistulae to maintain mean arterial pressure and mesenteric blood flow. In rats with 
aortocaval fistulae, Guo and Tabrizchi (2008) increased mean arterial pressure using 
noradrenaline and vasopressin. However, the mean arterial pressure of these rats was not 
decreased by sodium nitroprusside. Cardiac index and arterial resistance remained 
unchanged with all treatments. Aortocaval fistulae have a substantial influence over total 
peripheral resistance produced by the large volume of blood shunted from the aorta into 
the inferior vena cava. Similarly, as the fistula has a large conductance it has great 
influence over venous return and therefore cardiac output. Given that cardiac index and 
total peripheral resistance are seemingly invariable in rats with aortocaval fistula, a more 
stable mean arterial pressure is expected than in sham-operated rats. 
4.6. Baseline haemodynamic values of rats with and without aortocaval fistulae 
In this study, the mean arterial pressures of rats with and without aortocaval 
fistulae were slightly lower and the heart rates generally higher than those of age matched 
studies (Guo and Tabrizchi, 2008; Huang et al. , 1992). The different experimental 
protocols (e.g. anesthetics, fistula sizes) may explain the variable findings. Regardless, all 
studies have concluded that rats with and without aortocaval fistulae have similar mean 
arterial pressures and heart rates (Figure 5AB). 
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Mesenteric and renal blood flows and conductances were reduced in rats with 
aortocaval fi stulae compared to sham operated rats, whereas the iliac blood flows and 
conductances were similar (Figure 6BD). Reduced renal blood flow had been previously 
measured by microspheres at five weeks after fistula induction (Huang et al., 1992). In 
rats with aortocaval fistulae, total peripheral resistance is decreased, although increased 
cardiac output maintains a normal mean arterial pressure (Huang et al. , 1992). Systemic 
vasoconstriction likely occurs as a mechanism to increase total peripheral resistance and 
aid in maintaining a normal mean arterial pressure. As the renal and mesenteric vascular 
beds have larger blood flows than the hindquarters, and therefore greater propensities to 
influence total peripheral resistance, it may be reasonable to assume that they would 
constrict while the hindquarter conductance might remain unchanged . 
4.7. Sources of error 
In sham-operated rats, the mean mesenteric blood flows of the losartan and PD 
1233 19 groups were significantly lower than those of the captopril and normal saline 
groups. Furthermore, the mean mesenteric conductance of the losartan group was 
significantly lower than those of the captopril and normal sal ine groups. This source of 
error was carried throughout the analysis of drug effects in sham-operated rats and 111 
their comparison to rats with aortocaval fistulae. 
Also, the use of captopril in this study highlighted the incomplete attenuation of 
the RAAS by ACE inhibition in rats with a011ocaval fistu lae. As the captopril group was 
intended to provide an overall assessment of the integrated AT 1 and AT 2 receptor 
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influence on regional haemodynamics, it may not have been accurate to compare the 
overall influence of Ang II in rats with and without aortocaval fistulae based on data 
obtained by captopril inhibition of ACE. 
4.8. Future studies 
It would be interesting to test whether the simultaneous effects of losartan and PD 
123319 are comparable to those of captopril in rats with and without aortocaval fistulae. 
Furthermore, it would be interesting to assay for ACE-independent Ang II production at 
the cellular level within the vascular and perivascular tissues of rats with aortocaval 
fistulae. In addition, dose response curves to losartan following pretreatment with PD 
123319, and vice versa, might help to more accurately indicate the level of control that 
each receptor subtype exerts over regional haemodynamics in rats with and without 
aortocaval fistulae. Finally, quantitatively examining AT1 and AT2 receptor distribution 
might provide additional information regarding the mechanism of altered Ang II control 
of regional haemodynamics in rats with aortocaval fistulae. 
4.9. Conclusion 
Ang II is more active in the continuous control regional haemodynamics in rats 
with aortocaval fistulae than in sham-operated rats. In rats with aortocaval fistulae, AT 1 
receptors are more active than AT 2 receptors in regulating regional blood flows and 
conductances, whereas the input from AT 1 and AT2 receptors in sham-operated rats is 
regionally specific. These findings suggest that the RAAS is altered in rats with 
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aortocaval fistulae to favor vasoconstriction, possibly as a mechanism of maintaining a 
normal mean arterial pressure despite a large decrease in total peripheral resistance. 
Rats with aortocaval fistulae are a model of decreased systemic blood flow. The 
results of this study suggest that AT 1 receptor antagonism is more effective at increasing 
regional blood flow than ACE inhibition, in rats with aortocaval fistulae. This may be 
true of other pathological conditions in which tissue ischaemia results from systemic 
vasoconstriction and decreased systemic blood flow. 
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